Quarterly Report (10-q)

Date : 07/29/2019 @ 9:18PM
Source : Edgar (US Regulatory)
Stock : Johnson and Johnson (JNJ)
Quote : 127.7  -8.47 (-6.22%) @ 9:25PM
After Hours
Last Trade
Last $ 127.87 ▲ 0.17 (0.13%)

Quarterly Report (10-q)

false--12-29Q2201900002004062480000002510000001100000000220000000000.901.740.951.851.001.0043200000004320000000311984300031198430000.002500.006500.011500.016500.01650.01950.02050.02250.02450.02450.026250.0290.02950.02950.033750.0340.0350.03550.03550.036250.03700.03750.030.043750.04500.04500.04850.04950.05500.05850.05950.06730.0695440000000044000000004400000000440000000030000000010000000020000000002000000004400000040000000160000003900000034600000018300000010600000044000000510000001030000003400000035000000457519000477778000 0000200406 2018-12-31 2019-06-30 0000200406 2019-07-24 0000200406 jnj:A0.250NotesDue2022Member 2018-12-31 2019-06-30 0000200406 jnj:A4.75NotesDue2019Member 2018-12-31 2019-06-30 0000200406 us-gaap:CommonStockMember 2018-12-31 2019-06-30 0000200406 jnj:A5.50NotesDue2024Member 2018-12-31 2019-06-30 0000200406 jnj:A0.650NotesDue2024Member 2018-12-31 2019-06-30 0000200406 jnj:A1.150NotesDue2028Member 2018-12-31 2019-06-30 0000200406 jnj:A1.650NotesDue2035Member 2018-12-31 2019-06-30 0000200406 2018-12-30 0000200406 2019-06-30 0000200406 2019-04-01 2019-06-30 0000200406 2018-04-02 2018-07-01 0000200406 2018-01-01 2018-07-01 0000200406 2018-07-01 0000200406 2018-04-01 0000200406 us-gaap:CommonStockMember 2018-07-01 0000200406 us-gaap:RetainedEarningsMember 2018-04-02 2018-07-01 0000200406 us-gaap:RetainedEarningsMember 2018-07-01 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-04-01 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-07-01 0000200406 us-gaap:CommonStockMember 2018-04-01 0000200406 us-gaap:TreasuryStockMember 2018-07-01 0000200406 us-gaap:TreasuryStockMember 2018-04-02 2018-07-01 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-04-02 2018-07-01 0000200406 us-gaap:TreasuryStockMember 2018-04-01 0000200406 us-gaap:RetainedEarningsMember 2018-04-01 0000200406 us-gaap:CommonStockMember 2017-12-31 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000200406 us-gaap:RetainedEarningsMember 2017-12-31 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-07-01 0000200406 us-gaap:RetainedEarningsMember 2018-01-01 2018-07-01 0000200406 us-gaap:TreasuryStockMember 2017-12-31 0000200406 us-gaap:TreasuryStockMember 2018-01-01 2018-07-01 0000200406 2017-12-31 0000200406 us-gaap:RetainedEarningsMember 2019-06-30 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-30 0000200406 us-gaap:TreasuryStockMember 2018-12-30 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000200406 us-gaap:RetainedEarningsMember 2018-12-30 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 2019-06-30 0000200406 us-gaap:CommonStockMember 2019-06-30 0000200406 us-gaap:CommonStockMember 2018-12-30 0000200406 us-gaap:RetainedEarningsMember 2018-12-31 2019-06-30 0000200406 us-gaap:TreasuryStockMember 2019-06-30 0000200406 us-gaap:TreasuryStockMember 2018-12-31 2019-06-30 0000200406 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0000200406 2019-03-31 0000200406 us-gaap:TreasuryStockMember 2019-04-01 2019-06-30 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0000200406 us-gaap:RetainedEarningsMember 2019-03-31 0000200406 us-gaap:TreasuryStockMember 2019-03-31 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0000200406 us-gaap:CommonStockMember 2019-03-31 0000200406 srt:MaximumMember us-gaap:AccountingStandardsUpdate201602Member 2019-06-30 0000200406 srt:MinimumMember us-gaap:AccountingStandardsUpdate201602Member 2019-06-30 0000200406 us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember jnj:SupplyChainMember 2019-06-30 0000200406 us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember jnj:AdvancedSterilizationProductsMember 2018-12-30 0000200406 us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember jnj:SupplyChainMember 2018-12-30 0000200406 jnj:PatentsAndTrademarksMember 2019-06-30 0000200406 us-gaap:TrademarksMember 2019-06-30 0000200406 us-gaap:OtherIntangibleAssetsMember 2019-06-30 0000200406 jnj:PurchasedInProcessResearchAndDevelopmentMember 2019-06-30 0000200406 us-gaap:OtherIntangibleAssetsMember 2018-12-30 0000200406 jnj:PatentsAndTrademarksMember 2018-12-30 0000200406 us-gaap:TrademarksMember 2018-12-30 0000200406 jnj:PurchasedInProcessResearchAndDevelopmentMember 2018-12-30 0000200406 jnj:AurisHealthMember jnj:PurchasedInProcessResearchAndDevelopmentMember 2019-06-30 0000200406 jnj:PatentsAndTrademarksMember 2018-12-31 2019-06-30 0000200406 jnj:AliosBiopharmaIncMember jnj:PurchasedInProcessResearchAndDevelopmentMember 2018-12-31 2019-03-31 0000200406 us-gaap:OtherIntangibleAssetsMember 2018-12-31 2019-06-30 0000200406 jnj:AliosBiopharmaIncMember jnj:PurchasedInProcessResearchAndDevelopmentMember 2018-07-02 2018-09-30 0000200406 jnj:MedicalDevicesMember 2019-06-30 0000200406 jnj:ConsumerMember 2018-12-30 0000200406 jnj:PharmaceuticalMember 2019-06-30 0000200406 jnj:MedicalDevicesMember 2018-12-31 2019-06-30 0000200406 jnj:ConsumerMember 2018-12-31 2019-06-30 0000200406 jnj:MedicalDevicesMember 2018-12-30 0000200406 jnj:PharmaceuticalMember 2018-12-31 2019-06-30 0000200406 jnj:ConsumerMember 2019-06-30 0000200406 jnj:PharmaceuticalMember 2018-12-30 0000200406 us-gaap:HeldtomaturitySecuritiesMember 2019-06-30 0000200406 us-gaap:AvailableforsaleSecuritiesMember 2019-06-30 0000200406 us-gaap:HeldtomaturitySecuritiesMember us-gaap:SovereignDebtSecuritiesMember 2019-06-30 0000200406 us-gaap:HeldtomaturitySecuritiesMember us-gaap:BankTimeDepositsMember 2019-06-30 0000200406 us-gaap:HeldtomaturitySecuritiesMember jnj:OtherReverseRepurchaseAgreementsMember 2019-06-30 0000200406 us-gaap:AvailableforsaleSecuritiesMember us-gaap:CorporateDebtSecuritiesMember 2019-06-30 0000200406 us-gaap:HeldtomaturitySecuritiesMember us-gaap:MoneyMarketFundsMember 2019-06-30 0000200406 us-gaap:HeldtomaturitySecuritiesMember us-gaap:CorporateDebtSecuritiesMember 2019-06-30 0000200406 us-gaap:AvailableforsaleSecuritiesMember us-gaap:SovereignDebtSecuritiesMember 2019-06-30 0000200406 us-gaap:HeldtomaturitySecuritiesMember us-gaap:CashMember 2019-06-30 0000200406 us-gaap:AvailableforsaleSecuritiesMember us-gaap:USTreasuryAndGovernmentMember 2019-06-30 0000200406 us-gaap:HeldtomaturitySecuritiesMember us-gaap:SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember 2019-06-30 0000200406 us-gaap:LongTermDebtMember 2018-12-30 0000200406 jnj:CurrentPortionofLongtermDebtMember 2019-06-30 0000200406 jnj:CurrentPortionofLongtermDebtMember 2018-12-30 0000200406 us-gaap:LongTermDebtMember 2019-06-30 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember jnj:OtherIncomeExpenseNetMember 2018-12-31 2019-06-30 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember jnj:OtherIncomeExpenseNetMember 2019-04-01 2019-06-30 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember jnj:OtherIncomeExpenseNetMember 2018-04-02 2018-07-01 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember jnj:OtherIncomeExpenseNetMember 2018-01-01 2018-07-01 0000200406 us-gaap:CrossCurrencyInterestRateContractMember 2018-01-01 2018-07-01 0000200406 jnj:OtherIncomeExpenseNetMember 2018-12-31 2019-06-30 0000200406 jnj:OtherIncomeExpenseNetMember 2018-01-01 2018-07-01 0000200406 us-gaap:SaleOfSubsidiaryGainLossMember 2018-12-31 2019-06-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember 2018-12-31 2019-06-30 0000200406 us-gaap:SaleOfSubsidiaryGainLossMember 2018-01-01 2018-07-01 0000200406 jnj:NotesDuePeriodFifteenMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000200406 jnj:A4.50Debenturesdue2040Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-06-30 0000200406 jnj:A5.85Debenturesdue2038Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-06-30 0000200406 jnj:A4.375Notesdue2033Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-06-30 0000200406 jnj:A0.650NotesDue2024Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-06-30 0000200406 jnj:A3.55Notesdue2021Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000200406 jnj:A5.95Notesdue2037Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-06-30 0000200406 jnj:A2.625Notesdue2025Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000200406 jnj:A4.50Notesdue2043Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000200406 jnj:A2.95Debenturesdue2020Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000200406 jnj:A2.25Notesdue2022Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-06-30 0000200406 jnj:A6.73Debenturesdue2023Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000200406 jnj:A4.95Debenturesdue2033Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-06-30 0000200406 jnj:A5.95Notesdue2037Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000200406 jnj:A3.625Notesdue2037Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000200406 jnj:A2.05Notesdue2023Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000200406 jnj:A3.75Notesdue2047Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000200406 jnj:A1.950Notesdue2020Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-06-30 0000200406 jnj:A4.50Debenturesdue2040Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000200406 jnj:A2.45Notesdue2026Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000200406 jnj:A3.500Notesdue2048Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000200406 jnj:A0.250NotesDue2022Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-06-30 0000200406 jnj:A1.65Notesdue2021Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000200406 jnj:A3.500Notesdue2048Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-06-30 0000200406 jnj:A3.400Notesdue2038Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-06-30 0000200406 jnj:A6.95Notesdue2029Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000200406 jnj:A1.65Notesdue2021Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-06-30 0000200406 jnj:A3.400Notesdue2038Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000200406 jnj:A1.950Notesdue2020Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000200406 jnj:A5.50NotesDue2024Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000200406 jnj:A3.75Notesdue2047Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-06-30 0000200406 jnj:A1.650NotesDue2035Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-06-30 0000200406 jnj:A4.85Notesdue2041Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-06-30 0000200406 jnj:NotesDuePeriodFifteenMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-06-30 0000200406 jnj:A4.50Notesdue2043Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-06-30 0000200406 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000200406 jnj:A2.95Debenturesdue2020Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-06-30 0000200406 jnj:A3.70Notesdue2046Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000200406 jnj:A2.05Notesdue2023Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-06-30 0000200406 jnj:A5.50NotesDue2024Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-06-30 0000200406 jnj:A3.625Notesdue2037Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-06-30 0000200406 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-06-30 0000200406 jnj:A2.95Notesdue2027Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000200406 jnj:A2.45Notesdue2026Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-06-30 0000200406 jnj:A1.150NotesDue2028Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000200406 jnj:A0.650NotesDue2024Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000200406 jnj:A2.95Notesdue2027Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-06-30 0000200406 jnj:A6.95Notesdue2029Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-06-30 0000200406 jnj:A3ZeroCouponConvertibleSubordinatedDebenturesduein2020Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000200406 jnj:A2.900Notesdue2028Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-06-30 0000200406 jnj:A2.625Notesdue2025Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-06-30 0000200406 jnj:A3.55Notesdue2036Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000200406 jnj:A3.55Notesdue2036Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-06-30 0000200406 jnj:A3ZeroCouponConvertibleSubordinatedDebenturesduein2020Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-06-30 0000200406 jnj:A2.25Notesdue2022Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000200406 jnj:A6.73Debenturesdue2023Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-06-30 0000200406 jnj:A3.55Notesdue2021Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-06-30 0000200406 jnj:A4.95Debenturesdue2033Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000200406 jnj:A1.150NotesDue2028Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-06-30 0000200406 jnj:A2.45Notesdue2021Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000200406 jnj:A5.85Debenturesdue2038Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000200406 jnj:A3.375Notesdue2023Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000200406 jnj:A4.85Notesdue2041Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000200406 jnj:A4.375Notesdue2033Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000200406 jnj:A3.375Notesdue2023Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-06-30 0000200406 jnj:A0.250NotesDue2022Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000200406 jnj:A2.900Notesdue2028Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000200406 jnj:A2.45Notesdue2021Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-06-30 0000200406 jnj:A3.70Notesdue2046Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-06-30 0000200406 jnj:A1.650NotesDue2035Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember jnj:InterestIncomeExpenseNetMember 2018-01-01 2018-07-01 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2018-01-01 2018-07-01 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember jnj:OtherIncomeExpenseNetMember 2018-01-01 2018-07-01 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember jnj:OtherIncomeExpenseNetMember 2018-12-31 2019-06-30 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember jnj:InterestIncomeExpenseNetMember 2018-12-31 2019-06-30 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2018-12-31 2019-06-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember jnj:OtherIncomeExpenseNetMember 2018-01-01 2018-07-01 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:CostOfSalesMember 2018-01-01 2018-07-01 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember jnj:InterestIncomeExpenseNetMember 2018-12-31 2019-06-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:CostOfSalesMember 2018-12-31 2019-06-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember jnj:OtherIncomeExpenseNetMember 2018-01-01 2018-07-01 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember jnj:InterestIncomeExpenseNetMember 2018-01-01 2018-07-01 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SalesMember 2018-01-01 2018-07-01 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2018-12-31 2019-06-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember jnj:OtherIncomeExpenseNetMember 2018-12-31 2019-06-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2018-12-31 2019-06-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2018-12-31 2019-06-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember jnj:InterestIncomeExpenseNetMember 2018-01-01 2018-07-01 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2018-12-31 2019-06-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:SalesMember 2018-01-01 2018-07-01 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember jnj:OtherIncomeExpenseNetMember 2018-12-31 2019-06-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:SalesMember 2018-01-01 2018-07-01 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-07-01 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember jnj:OtherIncomeExpenseNetMember 2018-01-01 2018-07-01 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:SalesMember 2018-12-31 2019-06-30 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-07-01 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:SalesMember 2018-12-31 2019-06-30 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SalesMember 2018-12-31 2019-06-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2018-12-31 2019-06-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember jnj:InterestIncomeExpenseNetMember 2018-12-31 2019-06-30 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember jnj:InterestIncomeExpenseNetMember 2018-12-31 2019-06-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2018-01-01 2018-07-01 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-07-01 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember jnj:OtherIncomeExpenseNetMember 2018-01-01 2018-07-01 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember jnj:InterestIncomeExpenseNetMember 2018-12-31 2019-06-30 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-07-01 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember jnj:InterestIncomeExpenseNetMember 2018-01-01 2018-07-01 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember jnj:OtherIncomeExpenseNetMember 2018-12-31 2019-06-30 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:SalesMember 2018-01-01 2018-07-01 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:SalesMember 2018-12-31 2019-06-30 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2018-12-31 2019-06-30 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ResearchAndDevelopmentExpenseMember 2018-12-31 2019-06-30 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:CostOfSalesMember 2018-12-31 2019-06-30 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2018-01-01 2018-07-01 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember jnj:OtherIncomeExpenseNetMember 2018-12-31 2019-06-30 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-07-01 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:SalesMember 2018-12-31 2019-06-30 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember jnj:InterestIncomeExpenseNetMember 2018-01-01 2018-07-01 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:SalesMember 2018-01-01 2018-07-01 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:CostOfSalesMember 2018-01-01 2018-07-01 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member 2019-06-30 0000200406 us-gaap:ForeignExchangeContractMember 2019-06-30 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member 2018-12-30 0000200406 us-gaap:FairValueInputsLevel3Member 2019-06-30 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member 2018-12-30 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member 2019-06-30 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member 2019-06-30 0000200406 us-gaap:FairValueInputsLevel1Member 2019-06-30 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel1Member 2019-06-30 0000200406 us-gaap:InterestRateContractMember 2019-06-30 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel3Member 2019-06-30 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member 2019-06-30 0000200406 us-gaap:FairValueInputsLevel2Member 2018-12-30 0000200406 us-gaap:FairValueInputsLevel2Member 2019-06-30 0000200406 us-gaap:OtherNoncurrentLiabilitiesMember 2019-06-30 0000200406 us-gaap:ForeignExchangeContractMember 2018-12-30 0000200406 us-gaap:OtherNoncurrentLiabilitiesMember 2018-12-30 0000200406 us-gaap:EquitySecuritiesMember 2019-06-30 0000200406 us-gaap:EquitySecuritiesMember jnj:EquityInvestmentswithoutReadilyDeterminableValueMember 2018-12-31 2019-06-30 0000200406 us-gaap:FairValueInputsLevel3Member 2018-12-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember 2018-12-30 0000200406 us-gaap:InterestRateContractMember 2018-12-30 0000200406 us-gaap:EquitySecuritiesMember 2018-12-30 0000200406 us-gaap:OtherCurrentLiabilitiesMember 2019-06-30 0000200406 us-gaap:FairValueInputsLevel1Member 2018-12-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember 2019-06-30 0000200406 2018-01-01 2018-12-30 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember jnj:InterestIncomeExpenseNetMember 2018-04-02 2018-07-01 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:SalesMember 2018-04-02 2018-07-01 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:CostOfSalesMember 2019-04-01 2019-06-30 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2018-04-02 2018-07-01 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:SalesMember 2018-04-02 2018-07-01 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SalesMember 2019-04-01 2019-06-30 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember jnj:InterestIncomeExpenseNetMember 2019-04-01 2019-06-30 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember jnj:OtherIncomeExpenseNetMember 2018-04-02 2018-07-01 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember jnj:OtherIncomeExpenseNetMember 2019-04-01 2019-06-30 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:CostOfSalesMember 2019-04-01 2019-06-30 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:SalesMember 2019-04-01 2019-06-30 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember jnj:OtherIncomeExpenseNetMember 2018-04-02 2018-07-01 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:SalesMember 2019-04-01 2019-06-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:SalesMember 2018-04-02 2018-07-01 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember jnj:InterestIncomeExpenseNetMember 2019-04-01 2019-06-30 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:SalesMember 2019-04-01 2019-06-30 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ResearchAndDevelopmentExpenseMember 2019-04-01 2019-06-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:SalesMember 2019-04-01 2019-06-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember jnj:InterestIncomeExpenseNetMember 2018-04-02 2018-07-01 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2018-04-02 2018-07-01 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember jnj:OtherIncomeExpenseNetMember 2018-04-02 2018-07-01 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2018-04-02 2018-07-01 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:CostOfSalesMember 2018-04-02 2018-07-01 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2019-04-01 2019-06-30 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2019-04-01 2019-06-30 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2018-04-02 2018-07-01 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:SalesMember 2018-04-02 2018-07-01 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember jnj:InterestIncomeExpenseNetMember 2019-04-01 2019-06-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2018-04-02 2018-07-01 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember jnj:InterestIncomeExpenseNetMember 2019-04-01 2019-06-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember jnj:OtherIncomeExpenseNetMember 2018-04-02 2018-07-01 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember jnj:InterestIncomeExpenseNetMember 2018-04-02 2018-07-01 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2019-04-01 2019-06-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2019-04-01 2019-06-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember jnj:InterestIncomeExpenseNetMember 2018-04-02 2018-07-01 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember jnj:OtherIncomeExpenseNetMember 2019-04-01 2019-06-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember jnj:OtherIncomeExpenseNetMember 2019-04-01 2019-06-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2018-04-02 2018-07-01 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember jnj:InterestIncomeExpenseNetMember 2018-04-02 2018-07-01 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SalesMember 2018-04-02 2018-07-01 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember jnj:OtherIncomeExpenseNetMember 2019-04-01 2019-06-30 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2019-04-01 2019-06-30 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember jnj:InterestIncomeExpenseNetMember 2019-04-01 2019-06-30 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:CostOfSalesMember 2018-04-02 2018-07-01 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember jnj:OtherIncomeExpenseNetMember 2019-04-01 2019-06-30 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2019-04-01 2019-06-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2018-04-02 2018-07-01 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2019-04-01 2019-06-30 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ResearchAndDevelopmentExpenseMember 2018-04-02 2018-07-01 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember jnj:OtherIncomeExpenseNetMember 2018-04-02 2018-07-01 0000200406 jnj:OtherIncomeExpenseNetMember 2018-04-02 2018-07-01 0000200406 us-gaap:CrossCurrencyInterestRateContractMember 2019-04-01 2019-06-30 0000200406 us-gaap:SaleOfSubsidiaryGainLossMember 2018-04-02 2018-07-01 0000200406 jnj:OtherIncomeExpenseNetMember 2019-04-01 2019-06-30 0000200406 us-gaap:CrossCurrencyInterestRateContractMember 2018-04-02 2018-07-01 0000200406 us-gaap:SaleOfSubsidiaryGainLossMember 2019-04-01 2019-06-30 0000200406 us-gaap:EquitySecuritiesMember jnj:EquityInvestmentswithoutReadilyDeterminableValueMember 2019-06-30 0000200406 us-gaap:EquitySecuritiesMember jnj:EquityInvestmentswithReadilyDeterminableValueMember 2019-06-30 0000200406 us-gaap:EquitySecuritiesMember jnj:EquityInvestmentswithoutReadilyDeterminableValueMember 2018-12-30 0000200406 us-gaap:EquitySecuritiesMember jnj:EquityInvestmentswithReadilyDeterminableValueMember 2018-12-31 2019-06-30 0000200406 us-gaap:EquitySecuritiesMember jnj:EquityInvestmentswithReadilyDeterminableValueMember 2018-12-30 0000200406 jnj:A3.55Notesdue2036Member 2019-06-30 0000200406 jnj:A2.95Notesdue2027Member 2019-06-30 0000200406 jnj:A1.950Notesdue2020Member 2019-06-30 0000200406 jnj:A4.50Debenturesdue2040Member 2019-06-30 0000200406 jnj:A1.150NotesDue2028Member 2019-06-30 0000200406 jnj:A3ZeroCouponConvertibleSubordinatedDebenturesduein2020Member 2019-06-30 0000200406 jnj:A0.650NotesDue2024Member 2019-06-30 0000200406 jnj:A2.625Notesdue2025Member 2019-06-30 0000200406 jnj:A4.375Notesdue2033Member 2019-06-30 0000200406 jnj:A1.65Notesdue2021Member 2019-06-30 0000200406 jnj:A2.45Notesdue2026Member 2019-06-30 0000200406 jnj:A3.625Notesdue2037Member 2019-06-30 0000200406 jnj:A3.70Notesdue2046Member 2019-06-30 0000200406 jnj:A5.85Debenturesdue2038Member 2019-06-30 0000200406 jnj:A2.45Notesdue2021Member 2019-06-30 0000200406 jnj:A4.50Notesdue2043Member 2019-06-30 0000200406 jnj:A3.55Notesdue2021Member 2019-06-30 0000200406 jnj:A4.95Debenturesdue2033Member 2019-06-30 0000200406 jnj:A2.95Debenturesdue2020Member 2019-06-30 0000200406 jnj:A3.375Notesdue2023Member 2019-06-30 0000200406 jnj:A3.500Notesdue2048Member 2019-06-30 0000200406 jnj:A5.95Notesdue2037Member 2019-06-30 0000200406 jnj:A3.75Notesdue2047Member 2019-06-30 0000200406 jnj:A4.85Notesdue2041Member 2019-06-30 0000200406 jnj:A2.900Notesdue2028Member 2019-06-30 0000200406 jnj:A1.650NotesDue2035Member 2019-06-30 0000200406 jnj:A5.50NotesDue2024Member 2019-06-30 0000200406 jnj:A6.73Debenturesdue2023Member 2019-06-30 0000200406 jnj:A2.25Notesdue2022Member 2019-06-30 0000200406 jnj:A0.250NotesDue2022Member 2019-06-30 0000200406 jnj:A6.95Notesdue2029Member 2019-06-30 0000200406 jnj:A2.05Notesdue2023Member 2019-06-30 0000200406 jnj:A3.400Notesdue2038Member 2019-06-30 0000200406 srt:MaximumMember us-gaap:ScenarioForecastMember 2019-07-01 2019-09-29 0000200406 srt:MinimumMember us-gaap:ScenarioForecastMember 2019-07-01 2019-09-29 0000200406 country:US 2018-12-31 2019-06-30 0000200406 us-gaap:ForeignPlanMember 2018-12-31 2019-06-30 0000200406 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2018-04-02 2018-07-01 0000200406 us-gaap:PensionPlansDefinedBenefitMember 2018-01-01 2018-07-01 0000200406 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2018-12-31 2019-06-30 0000200406 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-04-01 2019-06-30 0000200406 us-gaap:PensionPlansDefinedBenefitMember 2019-04-01 2019-06-30 0000200406 us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 2019-06-30 0000200406 us-gaap:PensionPlansDefinedBenefitMember 2018-04-02 2018-07-01 0000200406 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2018-01-01 2018-07-01 0000200406 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-12-31 2019-06-30 0000200406 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-06-30 0000200406 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-12-30 0000200406 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-06-30 0000200406 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-30 0000200406 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-12-30 0000200406 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-06-30 0000200406 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-12-31 2019-06-30 0000200406 us-gaap:AccumulatedTranslationAdjustmentMember 2019-06-30 0000200406 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 2019-06-30 0000200406 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-12-31 2019-06-30 0000200406 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-12-30 0000200406 jnj:ActelionMember jnj:PharmaceuticalMember 2018-01-01 2018-07-01 0000200406 jnj:ActelionMember jnj:PharmaceuticalMember 2018-04-02 2018-07-01 0000200406 us-gaap:OperatingSegmentsMember jnj:PharmaceuticalMember 2018-12-31 2019-06-30 0000200406 us-gaap:OperatingSegmentsMember jnj:MedicalDevicesMember 2019-04-01 2019-06-30 0000200406 jnj:ActelionMember jnj:PharmaceuticalMember 2019-04-01 2019-06-30 0000200406 us-gaap:OperatingSegmentsMember jnj:MedicalDevicesMember 2018-12-31 2019-06-30 0000200406 us-gaap:OperatingSegmentsMember jnj:ConsumerMember 2018-04-02 2018-07-01 0000200406 jnj:MedicalDevicesMember 2018-01-01 2018-07-01 0000200406 us-gaap:OperatingSegmentsMember jnj:ConsumerMember 2018-12-31 2019-06-30 0000200406 us-gaap:OperatingSegmentsMember jnj:PharmaceuticalMember 2018-04-02 2018-07-01 0000200406 us-gaap:OperatingSegmentsMember jnj:MedicalDevicesMember 2018-04-02 2018-07-01 0000200406 jnj:MedicalDevicesMember 2018-04-02 2018-07-01 0000200406 us-gaap:OperatingSegmentsMember jnj:PharmaceuticalMember 2019-04-01 2019-06-30 0000200406 jnj:ActelionMember jnj:PharmaceuticalMember 2018-12-31 2019-06-30 0000200406 us-gaap:OperatingSegmentsMember jnj:ADVANCEDMember jnj:MedicalDevicesMember 2019-04-01 2019-06-30 0000200406 jnj:MedicalDevicesMember 2019-04-01 2019-06-30 0000200406 us-gaap:OperatingSegmentsMember jnj:ConsumerMember 2019-04-01 2019-06-30 0000200406 us-gaap:OperatingSegmentsMember jnj:MedicalDevicesMember 2018-01-01 2018-07-01 0000200406 jnj:CizHoldingsCo.Ltd.Member jnj:ConsumerMember 2018-12-31 2019-06-30 0000200406 us-gaap:OperatingSegmentsMember jnj:ConsumerMember 2018-01-01 2018-07-01 0000200406 us-gaap:OperatingSegmentsMember jnj:PharmaceuticalMember 2018-01-01 2018-07-01 0000200406 jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-12-31 2019-06-30 0000200406 jnj:UPTRAVIMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-04-02 2018-07-01 0000200406 jnj:ZYTIGAMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-12-31 2019-06-30 0000200406 country:US jnj:ConsumerMember 2018-01-01 2018-07-01 0000200406 jnj:SPECIALTYMember jnj:MedicalDevicesMember jnj:SurgeryMember 2018-04-02 2018-07-01 0000200406 jnj:OtherMember country:US jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2019-04-01 2019-06-30 0000200406 jnj:WomensHealthMember us-gaap:NonUsMember jnj:ConsumerMember 2019-04-01 2019-06-30 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-12-31 2019-06-30 0000200406 jnj:SimponiSimponiAriaMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-12-31 2019-06-30 0000200406 jnj:ZYTIGAMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-04-02 2018-07-01 0000200406 jnj:HIPSMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-12-31 2019-06-30 0000200406 jnj:OtherOncologyMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-04-02 2018-07-01 0000200406 jnj:CONCERTAMethylphenidateMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-12-31 2019-06-30 0000200406 jnj:SPINEOTHERMember country:US jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-01-01 2018-07-01 0000200406 jnj:DARZALEXMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-12-31 2019-06-30 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-04-02 2018-07-01 0000200406 jnj:PharmaceuticalMember jnj:OncologyMember 2019-04-01 2019-06-30 0000200406 jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-12-31 2019-06-30 0000200406 us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:InterventionalSolutionsMember 2018-12-31 2019-06-30 0000200406 jnj:ZYTIGAMember country:US jnj:PharmaceuticalMember jnj:OncologyMember 2019-04-01 2019-06-30 0000200406 jnj:PROCRITEPREXMember country:US jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-12-31 2019-06-30 0000200406 jnj:IMBRUVICAMember jnj:PharmaceuticalMember jnj:OncologyMember 2019-04-01 2019-06-30 0000200406 jnj:BeautyMember country:US jnj:ConsumerMember 2018-04-02 2018-07-01 0000200406 jnj:TremfyaMember country:US jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-01-01 2018-07-01 0000200406 jnj:SPECIALTYMember country:US jnj:MedicalDevicesMember jnj:SurgeryMember 2018-01-01 2018-07-01 0000200406 country:US jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-12-31 2019-06-30 0000200406 jnj:ADVANCEDMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:SurgeryMember 2018-04-02 2018-07-01 0000200406 jnj:TRACLEERMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-12-31 2019-06-30 0000200406 country:US jnj:PharmaceuticalMember jnj:ImmunologyMember 2019-04-01 2019-06-30 0000200406 jnj:MedicalDevicesMember jnj:SurgeryMember 2019-04-01 2019-06-30 0000200406 jnj:TRAUMAMember country:US jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2019-04-01 2019-06-30 0000200406 jnj:HIPSMember country:US jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-04-02 2018-07-01 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember 2018-12-31 2019-06-30 0000200406 jnj:WomensHealthMember us-gaap:NonUsMember jnj:ConsumerMember 2018-12-31 2019-06-30 0000200406 jnj:TRAUMAMember country:US jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-01-01 2018-07-01 0000200406 jnj:OTHERNEUROSCIENCEMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2019-04-01 2019-06-30 0000200406 jnj:ADVANCEDMember country:US jnj:MedicalDevicesMember jnj:SurgeryMember 2019-04-01 2019-06-30 0000200406 jnj:XareltoMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-12-31 2019-06-30 0000200406 jnj:OtherImmunologyMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2019-04-01 2019-06-30 0000200406 jnj:VELCADEMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-04-02 2018-07-01 0000200406 jnj:DARZALEXMember jnj:PharmaceuticalMember jnj:OncologyMember 2019-04-01 2019-06-30 0000200406 jnj:OtherOncologyMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:OncologyMember 2019-04-01 2019-06-30 0000200406 jnj:OtherImmunologyMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-12-31 2019-06-30 0000200406 jnj:SPECIALTYMember country:US jnj:MedicalDevicesMember jnj:SurgeryMember 2018-12-31 2019-06-30 0000200406 jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-04-02 2018-07-01 0000200406 jnj:VELCADEMember country:US jnj:PharmaceuticalMember jnj:OncologyMember 2019-04-01 2019-06-30 0000200406 jnj:MedicalDevicesMember jnj:DiabetesCareMember 2018-04-02 2018-07-01 0000200406 jnj:OralCareMember jnj:ConsumerMember 2018-01-01 2018-07-01 0000200406 jnj:OtherImmunologyMember country:US jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-12-31 2019-06-30 0000200406 us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:DiabetesCareMember 2019-04-01 2019-06-30 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-12-31 2019-06-30 0000200406 jnj:StelaraMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-04-02 2018-07-01 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-12-31 2019-06-30 0000200406 jnj:TRAUMAMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-04-02 2018-07-01 0000200406 jnj:OTHERNEUROSCIENCEMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-12-31 2019-06-30 0000200406 jnj:DARZALEXMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-12-31 2019-06-30 0000200406 country:US jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2019-04-01 2019-06-30 0000200406 country:US jnj:PharmaceuticalMember 2018-04-02 2018-07-01 0000200406 jnj:KNEESMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-12-31 2019-06-30 0000200406 jnj:SURGICALMember jnj:MedicalDevicesMember jnj:VisionMember 2019-04-01 2019-06-30 0000200406 jnj:KNEESMember country:US jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-12-31 2019-06-30 0000200406 jnj:OTCMember us-gaap:NonUsMember jnj:ConsumerMember 2018-04-02 2018-07-01 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember 2019-04-01 2019-06-30 0000200406 country:US jnj:MedicalDevicesMember jnj:SurgeryMember 2018-04-02 2018-07-01 0000200406 jnj:SPINEOTHERMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2019-04-01 2019-06-30 0000200406 jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-12-31 2019-06-30 0000200406 us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2019-04-01 2019-06-30 0000200406 jnj:CONTACTLENSESOTHERMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:VisionMember 2018-01-01 2018-07-01 0000200406 jnj:BeautyMember us-gaap:NonUsMember jnj:ConsumerMember 2018-04-02 2018-07-01 0000200406 jnj:StelaraMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-04-02 2018-07-01 0000200406 jnj:SURGICALMember country:US jnj:MedicalDevicesMember jnj:VisionMember 2018-12-31 2019-06-30 0000200406 us-gaap:NonUsMember jnj:MedicalDevicesMember 2018-01-01 2018-07-01 0000200406 jnj:CONCERTAMethylphenidateMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2019-04-01 2019-06-30 0000200406 jnj:WoundCareandOtherMember us-gaap:NonUsMember jnj:ConsumerMember 2018-04-02 2018-07-01 0000200406 jnj:WomensHealthMember jnj:ConsumerMember 2018-12-31 2019-06-30 0000200406 jnj:PROCRITEPREXMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2019-04-01 2019-06-30 0000200406 jnj:RISPERDALCONSTAMember country:US jnj:PharmaceuticalMember jnj:NeuroscienceMember 2019-04-01 2019-06-30 0000200406 jnj:BabyCareMember country:US jnj:ConsumerMember 2018-04-02 2018-07-01 0000200406 jnj:WomensHealthMember jnj:ConsumerMember 2019-04-01 2019-06-30 0000200406 jnj:RemicadeMember country:US jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-12-31 2019-06-30 0000200406 jnj:OralCareMember us-gaap:NonUsMember jnj:ConsumerMember 2018-01-01 2018-07-01 0000200406 jnj:ADVANCEDMember country:US jnj:MedicalDevicesMember jnj:SurgeryMember 2018-12-31 2019-06-30 0000200406 jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2019-04-01 2019-06-30 0000200406 country:US jnj:PharmaceuticalMember 2019-04-01 2019-06-30 0000200406 jnj:OralCareMember country:US jnj:ConsumerMember 2019-04-01 2019-06-30 0000200406 jnj:TRACLEERMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-04-02 2018-07-01 0000200406 jnj:RISPERDALCONSTAMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-01-01 2018-07-01 0000200406 jnj:OtherImmunologyMember country:US jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-01-01 2018-07-01 0000200406 us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-04-02 2018-07-01 0000200406 jnj:IMBRUVICAMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-04-02 2018-07-01 0000200406 jnj:BabyCareMember jnj:ConsumerMember 2018-04-02 2018-07-01 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-04-02 2018-07-01 0000200406 jnj:SURGICALMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:VisionMember 2018-12-31 2019-06-30 0000200406 jnj:CONTACTLENSESOTHERMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:VisionMember 2019-04-01 2019-06-30 0000200406 jnj:HIPSMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2019-04-01 2019-06-30 0000200406 jnj:EDURANTrilpivirineMember country:US jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-12-31 2019-06-30 0000200406 jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2019-04-01 2019-06-30 0000200406 jnj:GENERALMember country:US jnj:MedicalDevicesMember jnj:SurgeryMember 2019-04-01 2019-06-30 0000200406 jnj:IMBRUVICAMember country:US jnj:PharmaceuticalMember jnj:OncologyMember 2018-04-02 2018-07-01 0000200406 jnj:UPTRAVIMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-12-31 2019-06-30 0000200406 country:US jnj:MedicalDevicesMember jnj:SurgeryMember 2018-12-31 2019-06-30 0000200406 country:US jnj:MedicalDevicesMember jnj:InterventionalSolutionsMember 2019-04-01 2019-06-30 0000200406 jnj:OtherMember country:US jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-12-31 2019-06-30 0000200406 jnj:PROCRITEPREXMember country:US jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2019-04-01 2019-06-30 0000200406 jnj:BabyCareMember us-gaap:NonUsMember jnj:ConsumerMember 2019-04-01 2019-06-30 0000200406 jnj:SPINEOTHERMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2019-04-01 2019-06-30 0000200406 jnj:OtherImmunologyMember country:US jnj:PharmaceuticalMember jnj:ImmunologyMember 2019-04-01 2019-06-30 0000200406 jnj:SimponiSimponiAriaMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2019-04-01 2019-06-30 0000200406 jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-04-02 2018-07-01 0000200406 jnj:GENERALMember country:US jnj:MedicalDevicesMember jnj:SurgeryMember 2018-01-01 2018-07-01 0000200406 jnj:SPECIALTYMember jnj:MedicalDevicesMember jnj:SurgeryMember 2019-04-01 2019-06-30 0000200406 jnj:RemicadeMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-12-31 2019-06-30 0000200406 jnj:MedicalDevicesMember jnj:DiabetesCareMember 2018-01-01 2018-07-01 0000200406 jnj:PharmaceuticalMember jnj:OncologyMember 2018-01-01 2018-07-01 0000200406 jnj:OTHERNEUROSCIENCEMember country:US jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-04-02 2018-07-01 0000200406 jnj:UPTRAVIMember country:US jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2019-04-01 2019-06-30 0000200406 jnj:VELCADEMember jnj:PharmaceuticalMember jnj:OncologyMember 2019-04-01 2019-06-30 0000200406 jnj:OTHERNEUROSCIENCEMember country:US jnj:PharmaceuticalMember jnj:NeuroscienceMember 2019-04-01 2019-06-30 0000200406 jnj:SPINEOTHERMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-04-02 2018-07-01 0000200406 jnj:OtherOncologyMember country:US jnj:PharmaceuticalMember jnj:OncologyMember 2018-12-31 2019-06-30 0000200406 us-gaap:NonUsMember 2018-12-31 2019-06-30 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2019-04-01 2019-06-30 0000200406 jnj:OTHERNEUROSCIENCEMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-12-31 2019-06-30 0000200406 jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-01-01 2018-07-01 0000200406 jnj:OTCMember jnj:ConsumerMember 2018-04-02 2018-07-01 0000200406 country:US jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-12-31 2019-06-30 0000200406 jnj:SURGICALMember country:US jnj:MedicalDevicesMember jnj:VisionMember 2018-04-02 2018-07-01 0000200406 jnj:EDURANTrilpivirineMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-04-02 2018-07-01 0000200406 us-gaap:NonUsMember jnj:MedicalDevicesMember 2018-04-02 2018-07-01 0000200406 jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember country:US jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-01-01 2018-07-01 0000200406 jnj:SPINEOTHERMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-04-02 2018-07-01 0000200406 jnj:HIPSMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-12-31 2019-06-30 0000200406 country:US jnj:MedicalDevicesMember 2018-12-31 2019-06-30 0000200406 jnj:StelaraMember country:US jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-04-02 2018-07-01 0000200406 jnj:RISPERDALCONSTAMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-12-31 2019-06-30 0000200406 jnj:RISPERDALCONSTAMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-04-02 2018-07-01 0000200406 jnj:RemicadeMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-12-31 2019-06-30 0000200406 jnj:XareltoMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2019-04-01 2019-06-30 0000200406 jnj:OtherInfectiousDiseasesMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-12-31 2019-06-30 0000200406 jnj:KNEESMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-04-02 2018-07-01 0000200406 jnj:TRACLEERMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2019-04-01 2019-06-30 0000200406 jnj:MedicalDevicesMember jnj:VisionMember 2018-04-02 2018-07-01 0000200406 jnj:StelaraMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2019-04-01 2019-06-30 0000200406 jnj:ZYTIGAMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:OncologyMember 2019-04-01 2019-06-30 0000200406 jnj:OtherMember country:US jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-01-01 2018-07-01 0000200406 jnj:SimponiSimponiAriaMember country:US jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-12-31 2019-06-30 0000200406 country:US jnj:ConsumerMember 2018-12-31 2019-06-30 0000200406 jnj:WoundCareandOtherMember us-gaap:NonUsMember jnj:ConsumerMember 2018-12-31 2019-06-30 0000200406 jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2019-04-01 2019-06-30 0000200406 jnj:StelaraMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2019-04-01 2019-06-30 0000200406 jnj:CONTACTLENSESOTHERMember jnj:MedicalDevicesMember jnj:VisionMember 2018-04-02 2018-07-01 0000200406 jnj:SPINEOTHERMember country:US jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-12-31 2019-06-30 0000200406 jnj:OtherOncologyMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-01-01 2018-07-01 0000200406 jnj:XareltoMember country:US jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-01-01 2018-07-01 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:OncologyMember 2019-04-01 2019-06-30 0000200406 jnj:RemicadeMember country:US jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-01-01 2018-07-01 0000200406 jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2019-04-01 2019-06-30 0000200406 jnj:OtherImmunologyMember country:US jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-04-02 2018-07-01 0000200406 jnj:ADVANCEDMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:SurgeryMember 2019-04-01 2019-06-30 0000200406 jnj:BabyCareMember jnj:ConsumerMember 2019-04-01 2019-06-30 0000200406 jnj:TRAUMAMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-01-01 2018-07-01 0000200406 jnj:SPECIALTYMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:SurgeryMember 2018-12-31 2019-06-30 0000200406 jnj:MedicalDevicesMember jnj:InterventionalSolutionsMember 2018-04-02 2018-07-01 0000200406 jnj:INVOKANAINVOKAMETMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2019-04-01 2019-06-30 0000200406 jnj:DARZALEXMember country:US jnj:PharmaceuticalMember jnj:OncologyMember 2018-01-01 2018-07-01 0000200406 jnj:ZYTIGAMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-01-01 2018-07-01 0000200406 jnj:IMBRUVICAMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-12-31 2019-06-30 0000200406 us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:VisionMember 2018-04-02 2018-07-01 0000200406 jnj:TRAUMAMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-12-31 2019-06-30 0000200406 jnj:BeautyMember country:US jnj:ConsumerMember 2018-01-01 2018-07-01 0000200406 jnj:EDURANTrilpivirineMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2019-04-01 2019-06-30 0000200406 jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-12-31 2019-06-30 0000200406 jnj:CONTACTLENSESOTHERMember country:US jnj:MedicalDevicesMember jnj:VisionMember 2018-12-31 2019-06-30 0000200406 jnj:TRAUMAMember country:US jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-12-31 2019-06-30 0000200406 us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:VisionMember 2018-01-01 2018-07-01 0000200406 jnj:ADVANCEDMember jnj:MedicalDevicesMember jnj:SurgeryMember 2019-04-01 2019-06-30 0000200406 jnj:INVOKANAINVOKAMETMember country:US jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-12-31 2019-06-30 0000200406 jnj:OralCareMember country:US jnj:ConsumerMember 2018-04-02 2018-07-01 0000200406 country:US jnj:PharmaceuticalMember jnj:OncologyMember 2019-04-01 2019-06-30 0000200406 jnj:PharmaceuticalMember 2019-04-01 2019-06-30 0000200406 country:US jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-01-01 2018-07-01 0000200406 us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:VisionMember 2018-12-31 2019-06-30 0000200406 jnj:CONTACTLENSESOTHERMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:VisionMember 2018-04-02 2018-07-01 0000200406 jnj:BabyCareMember country:US jnj:ConsumerMember 2019-04-01 2019-06-30 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-12-31 2019-06-30 0000200406 jnj:MedicalDevicesMember jnj:InterventionalSolutionsMember 2019-04-01 2019-06-30 0000200406 jnj:UPTRAVIMember country:US jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-12-31 2019-06-30 0000200406 jnj:TRACLEERMember country:US jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2019-04-01 2019-06-30 0000200406 country:US jnj:MedicalDevicesMember 2019-04-01 2019-06-30 0000200406 jnj:INVOKANAINVOKAMETMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2019-04-01 2019-06-30 0000200406 jnj:GENERALMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:SurgeryMember 2018-04-02 2018-07-01 0000200406 jnj:OtherInfectiousDiseasesMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2019-04-01 2019-06-30 0000200406 jnj:RISPERDALCONSTAMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-12-31 2019-06-30 0000200406 jnj:EDURANTrilpivirineMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-12-31 2019-06-30 0000200406 jnj:OralCareMember country:US jnj:ConsumerMember 2018-01-01 2018-07-01 0000200406 jnj:OtherOncologyMember jnj:PharmaceuticalMember jnj:OncologyMember 2019-04-01 2019-06-30 0000200406 jnj:BeautyMember jnj:ConsumerMember 2019-04-01 2019-06-30 0000200406 jnj:BeautyMember us-gaap:NonUsMember jnj:ConsumerMember 2018-12-31 2019-06-30 0000200406 jnj:ZYTIGAMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-04-02 2018-07-01 0000200406 country:US jnj:PharmaceuticalMember 2018-12-31 2019-06-30 0000200406 jnj:OTCMember country:US jnj:ConsumerMember 2018-12-31 2019-06-30 0000200406 country:US jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-04-02 2018-07-01 0000200406 jnj:TRACLEERMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-12-31 2019-06-30 0000200406 country:US jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-12-31 2019-06-30 0000200406 jnj:DARZALEXMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:OncologyMember 2019-04-01 2019-06-30 0000200406 jnj:OtherMember country:US jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-01-01 2018-07-01 0000200406 jnj:VELCADEMember country:US jnj:PharmaceuticalMember jnj:OncologyMember 2018-04-02 2018-07-01 0000200406 country:US jnj:ConsumerMember 2019-04-01 2019-06-30 0000200406 us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:SurgeryMember 2019-04-01 2019-06-30 0000200406 jnj:SPINEOTHERMember country:US jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2019-04-01 2019-06-30 0000200406 jnj:BabyCareMember country:US jnj:ConsumerMember 2018-12-31 2019-06-30 0000200406 jnj:TRACLEERMember country:US jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-12-31 2019-06-30 0000200406 jnj:OralCareMember us-gaap:NonUsMember jnj:ConsumerMember 2018-12-31 2019-06-30 0000200406 jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2019-04-01 2019-06-30 0000200406 jnj:PharmaceuticalMember jnj:OncologyMember 2018-12-31 2019-06-30 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-04-02 2018-07-01 0000200406 jnj:EDURANTrilpivirineMember country:US jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-04-02 2018-07-01 0000200406 jnj:WomensHealthMember us-gaap:NonUsMember jnj:ConsumerMember 2018-04-02 2018-07-01 0000200406 jnj:DARZALEXMember country:US jnj:PharmaceuticalMember jnj:OncologyMember 2018-12-31 2019-06-30 0000200406 jnj:StelaraMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-12-31 2019-06-30 0000200406 jnj:INVOKANAINVOKAMETMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-12-31 2019-06-30 0000200406 jnj:BeautyMember jnj:ConsumerMember 2018-04-02 2018-07-01 0000200406 jnj:HIPSMember country:US jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2019-04-01 2019-06-30 0000200406 jnj:OtherOncologyMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-12-31 2019-06-30 0000200406 jnj:IMBRUVICAMember country:US jnj:PharmaceuticalMember jnj:OncologyMember 2018-01-01 2018-07-01 0000200406 jnj:OtherMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2019-04-01 2019-06-30 0000200406 jnj:OPSUMITMember country:US jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-12-31 2019-06-30 0000200406 jnj:OPSUMITMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2019-04-01 2019-06-30 0000200406 jnj:OTHERNEUROSCIENCEMember country:US jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-12-31 2019-06-30 0000200406 jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember country:US jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-01-01 2018-07-01 0000200406 jnj:IMBRUVICAMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:OncologyMember 2019-04-01 2019-06-30 0000200406 jnj:EDURANTrilpivirineMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-04-02 2018-07-01 0000200406 jnj:TremfyaMember country:US jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-04-02 2018-07-01 0000200406 jnj:CONTACTLENSESOTHERMember jnj:MedicalDevicesMember jnj:VisionMember 2018-12-31 2019-06-30 0000200406 jnj:IMBRUVICAMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-01-01 2018-07-01 0000200406 jnj:CONCERTAMethylphenidateMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-04-02 2018-07-01 0000200406 jnj:CONCERTAMethylphenidateMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-01-01 2018-07-01 0000200406 country:US jnj:MedicalDevicesMember jnj:VisionMember 2018-04-02 2018-07-01 0000200406 jnj:ZYTIGAMember jnj:PharmaceuticalMember jnj:OncologyMember 2019-04-01 2019-06-30 0000200406 jnj:ADVANCEDMember jnj:MedicalDevicesMember jnj:SurgeryMember 2018-12-31 2019-06-30 0000200406 jnj:SimponiSimponiAriaMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2019-04-01 2019-06-30 0000200406 country:US jnj:MedicalDevicesMember jnj:VisionMember 2018-12-31 2019-06-30 0000200406 jnj:OPSUMITMember country:US jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2019-04-01 2019-06-30 0000200406 jnj:SURGICALMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:VisionMember 2018-01-01 2018-07-01 0000200406 country:US jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2019-04-01 2019-06-30 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-01-01 2018-07-01 0000200406 jnj:TremfyaMember country:US jnj:PharmaceuticalMember jnj:ImmunologyMember 2019-04-01 2019-06-30 0000200406 us-gaap:NonUsMember jnj:MedicalDevicesMember 2018-12-31 2019-06-30 0000200406 us-gaap:NonUsMember jnj:MedicalDevicesMember 2019-04-01 2019-06-30 0000200406 country:US jnj:MedicalDevicesMember jnj:VisionMember 2018-01-01 2018-07-01 0000200406 jnj:OtherInfectiousDiseasesMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-01-01 2018-07-01 0000200406 us-gaap:NonUsMember 2018-04-02 2018-07-01 0000200406 jnj:TRAUMAMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-01-01 2018-07-01 0000200406 jnj:OTHERNEUROSCIENCEMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-04-02 2018-07-01 0000200406 jnj:ZYTIGAMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-12-31 2019-06-30 0000200406 jnj:OtherMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-01-01 2018-07-01 0000200406 jnj:SPECIALTYMember country:US jnj:MedicalDevicesMember jnj:SurgeryMember 2019-04-01 2019-06-30 0000200406 jnj:PROCRITEPREXMember country:US jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-04-02 2018-07-01 0000200406 jnj:OtherMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2019-04-01 2019-06-30 0000200406 jnj:XareltoMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-04-02 2018-07-01 0000200406 jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-01-01 2018-07-01 0000200406 jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember country:US jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-12-31 2019-06-30 0000200406 jnj:RemicadeMember jnj:UNITEDSTATESExportsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-12-31 2019-06-30 0000200406 jnj:OralCareMember us-gaap:NonUsMember jnj:ConsumerMember 2018-04-02 2018-07-01 0000200406 jnj:RemicadeMember country:US jnj:PharmaceuticalMember jnj:ImmunologyMember 2019-04-01 2019-06-30 0000200406 jnj:SimponiSimponiAriaMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-04-02 2018-07-01 0000200406 jnj:OtherOncologyMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-12-31 2019-06-30 0000200406 jnj:RISPERDALCONSTAMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2019-04-01 2019-06-30 0000200406 jnj:HIPSMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-04-02 2018-07-01 0000200406 jnj:CONTACTLENSESOTHERMember country:US jnj:MedicalDevicesMember jnj:VisionMember 2019-04-01 2019-06-30 0000200406 jnj:OtherMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-12-31 2019-06-30 0000200406 jnj:BeautyMember us-gaap:NonUsMember jnj:ConsumerMember 2019-04-01 2019-06-30 0000200406 us-gaap:NonUsMember jnj:ConsumerMember 2018-12-31 2019-06-30 0000200406 jnj:RISPERDALCONSTAMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-01-01 2018-07-01 0000200406 jnj:CONCERTAMethylphenidateMember country:US jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-12-31 2019-06-30 0000200406 us-gaap:NonUsMember 2019-04-01 2019-06-30 0000200406 jnj:PharmaceuticalMember jnj:OncologyMember 2018-04-02 2018-07-01 0000200406 jnj:GENERALMember country:US jnj:MedicalDevicesMember jnj:SurgeryMember 2018-12-31 2019-06-30 0000200406 us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:SurgeryMember 2018-01-01 2018-07-01 0000200406 jnj:OtherMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-01-01 2018-07-01 0000200406 jnj:XareltoMember country:US jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2019-04-01 2019-06-30 0000200406 jnj:SURGICALMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:VisionMember 2019-04-01 2019-06-30 0000200406 jnj:OtherImmunologyMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-04-02 2018-07-01 0000200406 us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:SurgeryMember 2018-12-31 2019-06-30 0000200406 jnj:XareltoMember country:US jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-12-31 2019-06-30 0000200406 jnj:IMBRUVICAMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-12-31 2019-06-30 0000200406 jnj:HIPSMember country:US jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-01-01 2018-07-01 0000200406 jnj:OTHERNEUROSCIENCEMember country:US jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-01-01 2018-07-01 0000200406 jnj:DARZALEXMember country:US jnj:PharmaceuticalMember jnj:OncologyMember 2019-04-01 2019-06-30 0000200406 jnj:OtherMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2019-04-01 2019-06-30 0000200406 jnj:SimponiSimponiAriaMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-01-01 2018-07-01 0000200406 jnj:TRAUMAMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-04-02 2018-07-01 0000200406 jnj:OPSUMITMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-04-02 2018-07-01 0000200406 country:US jnj:MedicalDevicesMember jnj:SurgeryMember 2019-04-01 2019-06-30 0000200406 jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2019-04-01 2019-06-30 0000200406 jnj:RemicadeMember country:US jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-04-02 2018-07-01 0000200406 jnj:OtherInfectiousDiseasesMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-12-31 2019-06-30 0000200406 jnj:RemicadeMember jnj:UNITEDSTATESExportsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-01-01 2018-07-01 0000200406 jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2019-04-01 2019-06-30 0000200406 jnj:OralCareMember jnj:ConsumerMember 2018-04-02 2018-07-01 0000200406 jnj:UPTRAVIMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-04-02 2018-07-01 0000200406 jnj:VELCADEMember country:US jnj:PharmaceuticalMember jnj:OncologyMember 2018-12-31 2019-06-30 0000200406 country:US jnj:MedicalDevicesMember jnj:DiabetesCareMember 2018-12-31 2019-06-30 0000200406 jnj:UPTRAVIMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2019-04-01 2019-06-30 0000200406 country:US jnj:PharmaceuticalMember jnj:OncologyMember 2018-12-31 2019-06-30 0000200406 jnj:TRAUMAMember country:US jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-04-02 2018-07-01 0000200406 jnj:ADVANCEDMember country:US jnj:MedicalDevicesMember jnj:SurgeryMember 2018-01-01 2018-07-01 0000200406 country:US jnj:MedicalDevicesMember jnj:DiabetesCareMember 2018-04-02 2018-07-01 0000200406 jnj:WoundCareandOtherMember jnj:ConsumerMember 2018-12-31 2019-06-30 0000200406 jnj:OtherImmunologyMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-12-31 2019-06-30 0000200406 jnj:TRAUMAMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2019-04-01 2019-06-30 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-01-01 2018-07-01 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2019-04-01 2019-06-30 0000200406 jnj:BabyCareMember jnj:ConsumerMember 2018-12-31 2019-06-30 0000200406 jnj:WoundCareandOtherMember jnj:ConsumerMember 2019-04-01 2019-06-30 0000200406 country:US jnj:MedicalDevicesMember jnj:InterventionalSolutionsMember 2018-12-31 2019-06-30 0000200406 jnj:CONCERTAMethylphenidateMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2019-04-01 2019-06-30 0000200406 jnj:INVOKANAINVOKAMETMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-01-01 2018-07-01 0000200406 jnj:ADVANCEDMember country:US jnj:MedicalDevicesMember jnj:SurgeryMember 2018-04-02 2018-07-01 0000200406 jnj:SimponiSimponiAriaMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-12-31 2019-06-30 0000200406 jnj:CONTACTLENSESOTHERMember jnj:MedicalDevicesMember jnj:VisionMember 2018-01-01 2018-07-01 0000200406 jnj:WoundCareandOtherMember jnj:ConsumerMember 2018-04-02 2018-07-01 0000200406 jnj:XareltoMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-01-01 2018-07-01 0000200406 jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-01-01 2018-07-01 0000200406 jnj:CONCERTAMethylphenidateMember country:US jnj:PharmaceuticalMember jnj:NeuroscienceMember 2019-04-01 2019-06-30 0000200406 jnj:OTCMember us-gaap:NonUsMember jnj:ConsumerMember 2018-12-31 2019-06-30 0000200406 jnj:OtherImmunologyMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2019-04-01 2019-06-30 0000200406 jnj:RemicadeMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-04-02 2018-07-01 0000200406 jnj:HIPSMember country:US jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-12-31 2019-06-30 0000200406 jnj:RemicadeMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2019-04-01 2019-06-30 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-12-31 2019-06-30 0000200406 jnj:ConsumerMember 2018-01-01 2018-07-01 0000200406 jnj:KNEESMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2019-04-01 2019-06-30 0000200406 jnj:CONTACTLENSESOTHERMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:VisionMember 2018-12-31 2019-06-30 0000200406 jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-01-01 2018-07-01 0000200406 us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:InterventionalSolutionsMember 2018-04-02 2018-07-01 0000200406 jnj:RISPERDALCONSTAMember country:US jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-01-01 2018-07-01 0000200406 jnj:VELCADEMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-01-01 2018-07-01 0000200406 jnj:OtherOncologyMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-04-02 2018-07-01 0000200406 country:US jnj:MedicalDevicesMember jnj:VisionMember 2019-04-01 2019-06-30 0000200406 jnj:DARZALEXMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-04-02 2018-07-01 0000200406 jnj:WoundCareandOtherMember country:US jnj:ConsumerMember 2018-12-31 2019-06-30 0000200406 jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-12-31 2019-06-30 0000200406 jnj:OtherMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-12-31 2019-06-30 0000200406 jnj:TRACLEERMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2019-04-01 2019-06-30 0000200406 jnj:OtherInfectiousDiseasesMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-01-01 2018-07-01 0000200406 jnj:MedicalDevicesMember jnj:VisionMember 2019-04-01 2019-06-30 0000200406 jnj:PharmaceuticalMember jnj:NeuroscienceMember 2019-04-01 2019-06-30 0000200406 jnj:OralCareMember jnj:ConsumerMember 2019-04-01 2019-06-30 0000200406 jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-04-02 2018-07-01 0000200406 jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-12-31 2019-06-30 0000200406 jnj:GENERALMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:SurgeryMember 2019-04-01 2019-06-30 0000200406 jnj:GENERALMember jnj:MedicalDevicesMember jnj:SurgeryMember 2018-12-31 2019-06-30 0000200406 jnj:BeautyMember jnj:ConsumerMember 2018-01-01 2018-07-01 0000200406 jnj:OTCMember country:US jnj:ConsumerMember 2019-04-01 2019-06-30 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-01-01 2018-07-01 0000200406 jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-01-01 2018-07-01 0000200406 jnj:PROCRITEPREXMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-01-01 2018-07-01 0000200406 jnj:TremfyaMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2019-04-01 2019-06-30 0000200406 jnj:TRACLEERMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-01-01 2018-07-01 0000200406 jnj:SURGICALMember jnj:MedicalDevicesMember jnj:VisionMember 2018-04-02 2018-07-01 0000200406 jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-01-01 2018-07-01 0000200406 jnj:TRAUMAMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2019-04-01 2019-06-30 0000200406 jnj:EDURANTrilpivirineMember country:US jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2019-04-01 2019-06-30 0000200406 jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-12-31 2019-06-30 0000200406 jnj:GENERALMember jnj:MedicalDevicesMember jnj:SurgeryMember 2019-04-01 2019-06-30 0000200406 jnj:WomensHealthMember country:US jnj:ConsumerMember 2018-12-31 2019-06-30 0000200406 jnj:HIPSMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2019-04-01 2019-06-30 0000200406 country:US jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-04-02 2018-07-01 0000200406 jnj:UPTRAVIMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-12-31 2019-06-30 0000200406 country:US jnj:ConsumerMember 2018-04-02 2018-07-01 0000200406 jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-01-01 2018-07-01 0000200406 jnj:WomensHealthMember country:US jnj:ConsumerMember 2019-04-01 2019-06-30 0000200406 jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-04-02 2018-07-01 0000200406 jnj:KNEESMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-12-31 2019-06-30 0000200406 jnj:OtherMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-04-02 2018-07-01 0000200406 jnj:PharmaceuticalMember 2018-04-02 2018-07-01 0000200406 jnj:CONCERTAMethylphenidateMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-04-02 2018-07-01 0000200406 country:US jnj:MedicalDevicesMember jnj:DiabetesCareMember 2018-01-01 2018-07-01 0000200406 jnj:ADVANCEDMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:SurgeryMember 2018-01-01 2018-07-01 0000200406 country:US jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-04-02 2018-07-01 0000200406 jnj:StelaraMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-12-31 2019-06-30 0000200406 country:US jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2019-04-01 2019-06-30 0000200406 jnj:StelaraMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-01-01 2018-07-01 0000200406 jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-04-02 2018-07-01 0000200406 jnj:OPSUMITMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-12-31 2019-06-30 0000200406 jnj:SPECIALTYMember country:US jnj:MedicalDevicesMember jnj:SurgeryMember 2018-04-02 2018-07-01 0000200406 jnj:OtherInfectiousDiseasesMember country:US jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-12-31 2019-06-30 0000200406 jnj:TRAUMAMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-12-31 2019-06-30 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2019-04-01 2019-06-30 0000200406 jnj:BeautyMember us-gaap:NonUsMember jnj:ConsumerMember 2018-01-01 2018-07-01 0000200406 jnj:GENERALMember jnj:MedicalDevicesMember jnj:SurgeryMember 2018-04-02 2018-07-01 0000200406 us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:DiabetesCareMember 2018-12-31 2019-06-30 0000200406 jnj:TRACLEERMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-04-02 2018-07-01 0000200406 jnj:WomensHealthMember us-gaap:NonUsMember jnj:ConsumerMember 2018-01-01 2018-07-01 0000200406 jnj:SPINEOTHERMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-12-31 2019-06-30 0000200406 jnj:IMBRUVICAMember country:US jnj:PharmaceuticalMember jnj:OncologyMember 2019-04-01 2019-06-30 0000200406 country:US jnj:PharmaceuticalMember jnj:NeuroscienceMember 2019-04-01 2019-06-30 0000200406 jnj:StelaraMember country:US jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-01-01 2018-07-01 0000200406 jnj:SimponiSimponiAriaMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-01-01 2018-07-01 0000200406 jnj:StelaraMember country:US jnj:PharmaceuticalMember jnj:ImmunologyMember 2019-04-01 2019-06-30 0000200406 jnj:HIPSMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-01-01 2018-07-01 0000200406 jnj:WomensHealthMember jnj:ConsumerMember 2018-01-01 2018-07-01 0000200406 jnj:OtherMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-04-02 2018-07-01 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2019-04-01 2019-06-30 0000200406 jnj:EDURANTrilpivirineMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2019-04-01 2019-06-30 0000200406 jnj:CONCERTAMethylphenidateMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-12-31 2019-06-30 0000200406 jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember country:US jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-04-02 2018-07-01 0000200406 jnj:OtherMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-12-31 2019-06-30 0000200406 jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-04-02 2018-07-01 0000200406 country:US jnj:MedicalDevicesMember jnj:SurgeryMember 2018-01-01 2018-07-01 0000200406 jnj:BabyCareMember us-gaap:NonUsMember jnj:ConsumerMember 2018-01-01 2018-07-01 0000200406 jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-01-01 2018-07-01 0000200406 jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember country:US jnj:PharmaceuticalMember jnj:NeuroscienceMember 2019-04-01 2019-06-30 0000200406 jnj:INVOKANAINVOKAMETMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-12-31 2019-06-30 0000200406 jnj:OtherInfectiousDiseasesMember country:US jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2019-04-01 2019-06-30 0000200406 country:US jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-12-31 2019-06-30 0000200406 jnj:EDURANTrilpivirineMember country:US jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-01-01 2018-07-01 0000200406 jnj:RemicadeMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2019-04-01 2019-06-30 0000200406 jnj:DARZALEXMember country:US jnj:PharmaceuticalMember jnj:OncologyMember 2018-04-02 2018-07-01 0000200406 jnj:StelaraMember country:US jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-12-31 2019-06-30 0000200406 jnj:GENERALMember jnj:MedicalDevicesMember jnj:SurgeryMember 2018-01-01 2018-07-01 0000200406 jnj:SPECIALTYMember jnj:MedicalDevicesMember jnj:SurgeryMember 2018-12-31 2019-06-30 0000200406 us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-12-31 2019-06-30 0000200406 jnj:OPSUMITMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-12-31 2019-06-30 0000200406 jnj:SPECIALTYMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:SurgeryMember 2019-04-01 2019-06-30 0000200406 jnj:ZYTIGAMember country:US jnj:PharmaceuticalMember jnj:OncologyMember 2018-12-31 2019-06-30 0000200406 jnj:MedicalDevicesMember jnj:InterventionalSolutionsMember 2018-01-01 2018-07-01 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2019-04-01 2019-06-30 0000200406 jnj:OtherMember country:US jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2019-04-01 2019-06-30 0000200406 jnj:MedicalDevicesMember jnj:SurgeryMember 2018-12-31 2019-06-30 0000200406 jnj:INVOKANAINVOKAMETMember country:US jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-01-01 2018-07-01 0000200406 jnj:OtherMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2019-04-01 2019-06-30 0000200406 jnj:TremfyaMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-12-31 2019-06-30 0000200406 jnj:CONTACTLENSESOTHERMember country:US jnj:MedicalDevicesMember jnj:VisionMember 2018-01-01 2018-07-01 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember 2018-01-01 2018-07-01 0000200406 jnj:INVOKANAINVOKAMETMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-04-02 2018-07-01 0000200406 jnj:UPTRAVIMember country:US jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-04-02 2018-07-01 0000200406 jnj:EDURANTrilpivirineMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-12-31 2019-06-30 0000200406 jnj:GENERALMember country:US jnj:MedicalDevicesMember jnj:SurgeryMember 2018-04-02 2018-07-01 0000200406 jnj:OralCareMember us-gaap:NonUsMember jnj:ConsumerMember 2019-04-01 2019-06-30 0000200406 jnj:OTCMember jnj:ConsumerMember 2018-12-31 2019-06-30 0000200406 country:US jnj:PharmaceuticalMember jnj:OncologyMember 2018-01-01 2018-07-01 0000200406 jnj:RISPERDALCONSTAMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2019-04-01 2019-06-30 0000200406 jnj:XareltoMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-04-02 2018-07-01 0000200406 jnj:RemicadeMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-01-01 2018-07-01 0000200406 jnj:OtherInfectiousDiseasesMember country:US jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-04-02 2018-07-01 0000200406 jnj:BabyCareMember us-gaap:NonUsMember jnj:ConsumerMember 2018-12-31 2019-06-30 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-04-02 2018-07-01 0000200406 jnj:VELCADEMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-01-01 2018-07-01 0000200406 us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-01-01 2018-07-01 0000200406 jnj:OTCMember country:US jnj:ConsumerMember 2018-01-01 2018-07-01 0000200406 jnj:PROCRITEPREXMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-12-31 2019-06-30 0000200406 jnj:OPSUMITMember country:US jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-01-01 2018-07-01 0000200406 jnj:UPTRAVIMember country:US jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-01-01 2018-07-01 0000200406 jnj:OTHERNEUROSCIENCEMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2019-04-01 2019-06-30 0000200406 jnj:BabyCareMember jnj:ConsumerMember 2018-01-01 2018-07-01 0000200406 jnj:OPSUMITMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-01-01 2018-07-01 0000200406 jnj:XareltoMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-01-01 2018-07-01 0000200406 country:US 2019-04-01 2019-06-30 0000200406 jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-04-02 2018-07-01 0000200406 jnj:TremfyaMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-12-31 2019-06-30 0000200406 jnj:VELCADEMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:OncologyMember 2019-04-01 2019-06-30 0000200406 country:US jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-04-02 2018-07-01 0000200406 jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-04-02 2018-07-01 0000200406 us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:InterventionalSolutionsMember 2019-04-01 2019-06-30 0000200406 jnj:XareltoMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-12-31 2019-06-30 0000200406 jnj:ADVANCEDMember jnj:MedicalDevicesMember jnj:SurgeryMember 2018-04-02 2018-07-01 0000200406 country:US jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-01-01 2018-07-01 0000200406 jnj:TremfyaMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-04-02 2018-07-01 0000200406 jnj:INVOKANAINVOKAMETMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-04-02 2018-07-01 0000200406 jnj:DARZALEXMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-01-01 2018-07-01 0000200406 jnj:BeautyMember jnj:ConsumerMember 2018-12-31 2019-06-30 0000200406 jnj:RemicadeMember jnj:UNITEDSTATESExportsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-04-02 2018-07-01 0000200406 jnj:SPINEOTHERMember country:US jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-04-02 2018-07-01 0000200406 jnj:WoundCareandOtherMember jnj:ConsumerMember 2018-01-01 2018-07-01 0000200406 jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-01-01 2018-07-01 0000200406 country:US jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-12-31 2019-06-30 0000200406 jnj:PROCRITEPREXMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-01-01 2018-07-01 0000200406 jnj:WomensHealthMember country:US jnj:ConsumerMember 2018-04-02 2018-07-01 0000200406 jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2019-04-01 2019-06-30 0000200406 jnj:SPINEOTHERMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-12-31 2019-06-30 0000200406 jnj:RemicadeMember jnj:UNITEDSTATESExportsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2019-04-01 2019-06-30 0000200406 jnj:UPTRAVIMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-01-01 2018-07-01 0000200406 jnj:OtherInfectiousDiseasesMember country:US jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-01-01 2018-07-01 0000200406 jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-04-02 2018-07-01 0000200406 jnj:OTHERNEUROSCIENCEMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-01-01 2018-07-01 0000200406 jnj:TRACLEERMember country:US jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-04-02 2018-07-01 0000200406 jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-12-31 2019-06-30 0000200406 jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember country:US jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-04-02 2018-07-01 0000200406 jnj:PROCRITEPREXMember country:US jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-01-01 2018-07-01 0000200406 jnj:OtherOncologyMember country:US jnj:PharmaceuticalMember jnj:OncologyMember 2019-04-01 2019-06-30 0000200406 jnj:RISPERDALCONSTAMember country:US jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-12-31 2019-06-30 0000200406 jnj:ZYTIGAMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-01-01 2018-07-01 0000200406 jnj:OTCMember jnj:ConsumerMember 2018-01-01 2018-07-01 0000200406 jnj:TRACLEERMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-01-01 2018-07-01 0000200406 jnj:TremfyaMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-01-01 2018-07-01 0000200406 jnj:OtherMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-12-31 2019-06-30 0000200406 jnj:OTCMember us-gaap:NonUsMember jnj:ConsumerMember 2018-01-01 2018-07-01 0000200406 jnj:UPTRAVIMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2019-04-01 2019-06-30 0000200406 jnj:BeautyMember country:US jnj:ConsumerMember 2018-12-31 2019-06-30 0000200406 country:US jnj:MedicalDevicesMember jnj:InterventionalSolutionsMember 2018-04-02 2018-07-01 0000200406 jnj:ADVANCEDMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:SurgeryMember 2018-12-31 2019-06-30 0000200406 jnj:OtherInfectiousDiseasesMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2019-04-01 2019-06-30 0000200406 us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:VisionMember 2019-04-01 2019-06-30 0000200406 jnj:WoundCareandOtherMember us-gaap:NonUsMember jnj:ConsumerMember 2019-04-01 2019-06-30 0000200406 jnj:SURGICALMember country:US jnj:MedicalDevicesMember jnj:VisionMember 2018-01-01 2018-07-01 0000200406 jnj:SimponiSimponiAriaMember country:US jnj:PharmaceuticalMember jnj:ImmunologyMember 2019-04-01 2019-06-30 0000200406 jnj:VELCADEMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-12-31 2019-06-30 0000200406 jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-04-02 2018-07-01 0000200406 jnj:WoundCareandOtherMember country:US jnj:ConsumerMember 2019-04-01 2019-06-30 0000200406 jnj:OtherInfectiousDiseasesMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-04-02 2018-07-01 0000200406 jnj:KNEESMember country:US jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-01-01 2018-07-01 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-01-01 2018-07-01 0000200406 jnj:OralCareMember jnj:ConsumerMember 2018-12-31 2019-06-30 0000200406 jnj:RemicadeMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-01-01 2018-07-01 0000200406 jnj:VELCADEMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-12-31 2019-06-30 0000200406 country:US 2018-04-02 2018-07-01 0000200406 jnj:OtherOncologyMember country:US jnj:PharmaceuticalMember jnj:OncologyMember 2018-01-01 2018-07-01 0000200406 jnj:SURGICALMember country:US jnj:MedicalDevicesMember jnj:VisionMember 2019-04-01 2019-06-30 0000200406 country:US jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-12-31 2019-06-30 0000200406 jnj:IMBRUVICAMember country:US jnj:PharmaceuticalMember jnj:OncologyMember 2018-12-31 2019-06-30 0000200406 jnj:OtherMember country:US jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-04-02 2018-07-01 0000200406 jnj:OtherMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-01-01 2018-07-01 0000200406 jnj:IMBRUVICAMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-04-02 2018-07-01 0000200406 country:US jnj:PharmaceuticalMember jnj:OncologyMember 2018-04-02 2018-07-01 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-12-31 2019-06-30 0000200406 jnj:WoundCareandOtherMember country:US jnj:ConsumerMember 2018-01-01 2018-07-01 0000200406 jnj:VELCADEMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-04-02 2018-07-01 0000200406 jnj:MedicalDevicesMember jnj:DiabetesCareMember 2018-12-31 2019-06-30 0000200406 jnj:SURGICALMember jnj:MedicalDevicesMember jnj:VisionMember 2018-12-31 2019-06-30 0000200406 jnj:TremfyaMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-04-02 2018-07-01 0000200406 jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-01-01 2018-07-01 0000200406 jnj:INVOKANAINVOKAMETMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-01-01 2018-07-01 0000200406 jnj:KNEESMember country:US jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-04-02 2018-07-01 0000200406 jnj:OPSUMITMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2019-04-01 2019-06-30 0000200406 jnj:OTCMember us-gaap:NonUsMember jnj:ConsumerMember 2019-04-01 2019-06-30 0000200406 us-gaap:NonUsMember jnj:ConsumerMember 2018-01-01 2018-07-01 0000200406 jnj:TremfyaMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-01-01 2018-07-01 0000200406 jnj:BabyCareMember country:US jnj:ConsumerMember 2018-01-01 2018-07-01 0000200406 country:US jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-04-02 2018-07-01 0000200406 jnj:TremfyaMember country:US jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-12-31 2019-06-30 0000200406 jnj:MedicalDevicesMember jnj:VisionMember 2018-12-31 2019-06-30 0000200406 jnj:UPTRAVIMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-01-01 2018-07-01 0000200406 jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-12-31 2019-06-30 0000200406 jnj:EDURANTrilpivirineMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-01-01 2018-07-01 0000200406 jnj:ConsumerMember 2019-04-01 2019-06-30 0000200406 jnj:WoundCareandOtherMember country:US jnj:ConsumerMember 2018-04-02 2018-07-01 0000200406 jnj:MedicalDevicesMember jnj:SurgeryMember 2018-01-01 2018-07-01 0000200406 jnj:DARZALEXMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-04-02 2018-07-01 0000200406 country:US jnj:MedicalDevicesMember 2018-04-02 2018-07-01 0000200406 jnj:MedicalDevicesMember jnj:SurgeryMember 2018-04-02 2018-07-01 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember 2018-04-02 2018-07-01 0000200406 jnj:HIPSMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-01-01 2018-07-01 0000200406 jnj:VELCADEMember country:US jnj:PharmaceuticalMember jnj:OncologyMember 2018-01-01 2018-07-01 0000200406 jnj:TRACLEERMember country:US jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-01-01 2018-07-01 0000200406 jnj:MedicalDevicesMember jnj:InterventionalSolutionsMember 2018-12-31 2019-06-30 0000200406 jnj:OtherMember country:US jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-12-31 2019-06-30 0000200406 jnj:RISPERDALCONSTAMember country:US jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-04-02 2018-07-01 0000200406 country:US jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2019-04-01 2019-06-30 0000200406 jnj:OPSUMITMember country:US jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-04-02 2018-07-01 0000200406 jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember country:US jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-12-31 2019-06-30 0000200406 jnj:KNEESMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-04-02 2018-07-01 0000200406 jnj:SPECIALTYMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:SurgeryMember 2018-01-01 2018-07-01 0000200406 jnj:KNEESMember country:US jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2019-04-01 2019-06-30 0000200406 jnj:ZYTIGAMember country:US jnj:PharmaceuticalMember jnj:OncologyMember 2018-04-02 2018-07-01 0000200406 jnj:IMBRUVICAMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-01-01 2018-07-01 0000200406 country:US jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-01-01 2018-07-01 0000200406 jnj:OTCMember country:US jnj:ConsumerMember 2018-04-02 2018-07-01 0000200406 jnj:KNEESMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2019-04-01 2019-06-30 0000200406 country:US 2018-12-31 2019-06-30 0000200406 jnj:BeautyMember country:US jnj:ConsumerMember 2019-04-01 2019-06-30 0000200406 jnj:OtherImmunologyMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-01-01 2018-07-01 0000200406 jnj:PharmaceuticalMember jnj:ImmunologyMember 2019-04-01 2019-06-30 0000200406 jnj:OtherMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-04-02 2018-07-01 0000200406 jnj:KNEESMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-01-01 2018-07-01 0000200406 country:US jnj:MedicalDevicesMember jnj:InterventionalSolutionsMember 2018-01-01 2018-07-01 0000200406 country:US jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-04-02 2018-07-01 0000200406 jnj:HIPSMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-04-02 2018-07-01 0000200406 jnj:PROCRITEPREXMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-12-31 2019-06-30 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-04-02 2018-07-01 0000200406 jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-12-31 2019-06-30 0000200406 country:US jnj:MedicalDevicesMember 2018-01-01 2018-07-01 0000200406 jnj:SimponiSimponiAriaMember country:US jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-01-01 2018-07-01 0000200406 jnj:XareltoMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2019-04-01 2019-06-30 0000200406 jnj:WomensHealthMember jnj:ConsumerMember 2018-04-02 2018-07-01 0000200406 jnj:OtherInfectiousDiseasesMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-04-02 2018-07-01 0000200406 jnj:EDURANTrilpivirineMember jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-01-01 2018-07-01 0000200406 jnj:PROCRITEPREXMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2019-04-01 2019-06-30 0000200406 jnj:OTHERNEUROSCIENCEMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-04-02 2018-07-01 0000200406 jnj:DARZALEXMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-01-01 2018-07-01 0000200406 jnj:OtherMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-04-02 2018-07-01 0000200406 jnj:INVOKANAINVOKAMETMember country:US jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-04-02 2018-07-01 0000200406 jnj:SPECIALTYMember jnj:MedicalDevicesMember jnj:SurgeryMember 2018-01-01 2018-07-01 0000200406 jnj:BabyCareMember us-gaap:NonUsMember jnj:ConsumerMember 2018-04-02 2018-07-01 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-01-01 2018-07-01 0000200406 us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:InterventionalSolutionsMember 2018-01-01 2018-07-01 0000200406 country:US jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-01-01 2018-07-01 0000200406 jnj:MedicalDevicesMember jnj:DiabetesCareMember 2019-04-01 2019-06-30 0000200406 country:US jnj:PharmaceuticalMember 2018-01-01 2018-07-01 0000200406 jnj:OtherImmunologyMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-04-02 2018-07-01 0000200406 jnj:OtherMember country:US jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-04-02 2018-07-01 0000200406 jnj:OTHERNEUROSCIENCEMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-01-01 2018-07-01 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-04-02 2018-07-01 0000200406 jnj:PROCRITEPREXMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-04-02 2018-07-01 0000200406 us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-01-01 2018-07-01 0000200406 jnj:PROCRITEPREXMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-04-02 2018-07-01 0000200406 jnj:SPINEOTHERMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-01-01 2018-07-01 0000200406 jnj:WomensHealthMember country:US jnj:ConsumerMember 2018-01-01 2018-07-01 0000200406 jnj:SURGICALMember jnj:MedicalDevicesMember jnj:VisionMember 2018-01-01 2018-07-01 0000200406 jnj:XareltoMember country:US jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-04-02 2018-07-01 0000200406 us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:DiabetesCareMember 2018-01-01 2018-07-01 0000200406 jnj:WoundCareandOtherMember us-gaap:NonUsMember jnj:ConsumerMember 2018-01-01 2018-07-01 0000200406 jnj:ZYTIGAMember country:US jnj:PharmaceuticalMember jnj:OncologyMember 2018-01-01 2018-07-01 0000200406 jnj:ADVANCEDMember jnj:MedicalDevicesMember jnj:SurgeryMember 2018-01-01 2018-07-01 0000200406 jnj:CONCERTAMethylphenidateMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-01-01 2018-07-01 0000200406 jnj:SimponiSimponiAriaMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-04-02 2018-07-01 0000200406 country:US jnj:MedicalDevicesMember jnj:DiabetesCareMember 2019-04-01 2019-06-30 0000200406 jnj:StelaraMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-01-01 2018-07-01 0000200406 us-gaap:NonUsMember 2018-01-01 2018-07-01 0000200406 jnj:OTCMember jnj:ConsumerMember 2019-04-01 2019-06-30 0000200406 country:US jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-01-01 2018-07-01 0000200406 jnj:TremfyaMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2019-04-01 2019-06-30 0000200406 jnj:OtherMember jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2018-01-01 2018-07-01 0000200406 jnj:OtherOncologyMember country:US jnj:PharmaceuticalMember jnj:OncologyMember 2018-04-02 2018-07-01 0000200406 jnj:ConsumerMember 2018-04-02 2018-07-01 0000200406 jnj:OtherImmunologyMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-01-01 2018-07-01 0000200406 jnj:OralCareMember country:US jnj:ConsumerMember 2018-12-31 2019-06-30 0000200406 jnj:CONTACTLENSESOTHERMember country:US jnj:MedicalDevicesMember jnj:VisionMember 2018-04-02 2018-07-01 0000200406 country:US jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2018-01-01 2018-07-01 0000200406 jnj:SPINEOTHERMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-01-01 2018-07-01 0000200406 jnj:GENERALMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:SurgeryMember 2018-12-31 2019-06-30 0000200406 us-gaap:NonUsMember jnj:ConsumerMember 2018-04-02 2018-07-01 0000200406 jnj:SPECIALTYMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:SurgeryMember 2018-04-02 2018-07-01 0000200406 jnj:SimponiSimponiAriaMember country:US jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-04-02 2018-07-01 0000200406 jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember country:US jnj:PharmaceuticalMember jnj:InfectiousDiseasesMember 2019-04-01 2019-06-30 0000200406 us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:DiabetesCareMember 2018-04-02 2018-07-01 0000200406 jnj:KNEESMember jnj:MedicalDevicesMember jnj:OrthopaedicsMember 2018-01-01 2018-07-01 0000200406 jnj:RemicadeMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:ImmunologyMember 2018-04-02 2018-07-01 0000200406 jnj:CONTACTLENSESOTHERMember jnj:MedicalDevicesMember jnj:VisionMember 2019-04-01 2019-06-30 0000200406 jnj:SURGICALMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:VisionMember 2018-04-02 2018-07-01 0000200406 us-gaap:NonUsMember jnj:ConsumerMember 2019-04-01 2019-06-30 0000200406 jnj:OtherOncologyMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:OncologyMember 2018-01-01 2018-07-01 0000200406 jnj:GENERALMember us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:SurgeryMember 2018-01-01 2018-07-01 0000200406 jnj:PharmaceuticalMember 2018-01-01 2018-07-01 0000200406 jnj:RISPERDALCONSTAMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-04-02 2018-07-01 0000200406 jnj:INVOKANAINVOKAMETMember country:US jnj:PharmaceuticalMember jnj:CardiovascularMetabolismOtherMember 2019-04-01 2019-06-30 0000200406 jnj:OPSUMITMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-04-02 2018-07-01 0000200406 jnj:CONCERTAMethylphenidateMember country:US jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-04-02 2018-07-01 0000200406 country:US 2018-01-01 2018-07-01 0000200406 us-gaap:NonUsMember jnj:MedicalDevicesMember jnj:SurgeryMember 2018-04-02 2018-07-01 0000200406 jnj:CONCERTAMethylphenidateMember country:US jnj:PharmaceuticalMember jnj:NeuroscienceMember 2018-01-01 2018-07-01 0000200406 jnj:OPSUMITMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:PulmonaryHypertensionMember 2018-01-01 2018-07-01 0000200406 jnj:MedicalDevicesMember jnj:VisionMember 2018-01-01 2018-07-01 0000200406 us-gaap:CorporateNonSegmentMember 2019-04-01 2019-06-30 0000200406 us-gaap:OperatingSegmentsMember 2019-04-01 2019-06-30 0000200406 us-gaap:CorporateNonSegmentMember 2018-01-01 2018-07-01 0000200406 us-gaap:OperatingSegmentsMember 2018-12-31 2019-06-30 0000200406 us-gaap:OperatingSegmentsMember 2018-04-02 2018-07-01 0000200406 us-gaap:CorporateNonSegmentMember 2018-12-31 2019-06-30 0000200406 us-gaap:OperatingSegmentsMember 2018-01-01 2018-07-01 0000200406 us-gaap:CorporateNonSegmentMember 2018-04-02 2018-07-01 0000200406 jnj:AsiaPacificAfricaMember 2018-01-01 2018-07-01 0000200406 jnj:AsiaPacificAfricaMember 2019-04-01 2019-06-30 0000200406 jnj:WesternHemisphereExcludingUSMember 2019-04-01 2019-06-30 0000200406 srt:EuropeMember 2018-01-01 2018-07-01 0000200406 srt:EuropeMember 2018-04-02 2018-07-01 0000200406 jnj:WesternHemisphereExcludingUSMember 2018-12-31 2019-06-30 0000200406 srt:EuropeMember 2018-12-31 2019-06-30 0000200406 jnj:AsiaPacificAfricaMember 2018-04-02 2018-07-01 0000200406 jnj:AsiaPacificAfricaMember 2018-12-31 2019-06-30 0000200406 jnj:WesternHemisphereExcludingUSMember 2018-04-02 2018-07-01 0000200406 srt:EuropeMember 2019-04-01 2019-06-30 0000200406 jnj:WesternHemisphereExcludingUSMember 2018-01-01 2018-07-01 0000200406 us-gaap:OperatingSegmentsMember jnj:ADVANCEDMember jnj:MedicalDevicesMember 2018-12-31 2019-06-30 0000200406 jnj:CizHoldingsCo.Ltd.Member 2019-06-30 0000200406 jnj:AdvancedSterilizationProductsMember 2019-04-01 2019-06-30 0000200406 us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember jnj:AdvancedSterilizationProductsMember 2019-04-01 0000200406 jnj:CizHoldingsCo.Ltd.Member 2018-10-23 2018-10-23 0000200406 jnj:AurisHealthMember 2019-04-01 0000200406 jnj:AurisHealthMember 2019-04-01 2019-06-30 0000200406 jnj:CizHoldingsCo.Ltd.Member 2019-01-16 0000200406 jnj:CizHoldingsCo.Ltd.Member 2019-01-17 0000200406 srt:MinimumMember jnj:AurisHealthMember 2019-04-01 0000200406 jnj:CizHoldingsCo.Ltd.Member 2018-10-22 0000200406 jnj:CizHoldingsCo.Ltd.Member 2018-12-31 2019-03-31 0000200406 srt:MaximumMember jnj:AurisHealthMember 2019-04-01 0000200406 jnj:PhysiomeshMember 2019-06-30 0000200406 jnj:PelvicMeshesMember 2019-06-30 0000200406 jnj:AsrMember 2019-06-30 0000200406 jnj:OpiodsMember 2019-06-30 0000200406 jnj:InvokanaMember 2019-06-30 0000200406 jnj:TalcMember 2019-06-30 0000200406 jnj:XareltoMember 2019-06-30 0000200406 jnj:DePuyASRU.S.Member us-gaap:SettledLitigationMember 2019-06-30 0000200406 jnj:BabyPowderMember us-gaap:JudicialRulingMember us-gaap:DamagesFromProductDefectsMember 2018-12-31 2019-06-30 0000200406 jnj:PinnacleAcetabularCupSystemMember 2019-06-30 0000200406 jnj:RisperdalMember 2019-06-30 0000200406 srt:MinimumMember jnj:SupplyChainMember 2019-06-30 0000200406 jnj:SupplyChainMember 2019-06-30 0000200406 us-gaap:CostOfSalesMember jnj:SupplyChainMember 2018-12-31 2019-06-30 0000200406 jnj:SupplyChainMember 2019-04-01 2019-06-30 0000200406 srt:MaximumMember jnj:SupplyChainMember 2019-06-30 0000200406 srt:MinimumMember jnj:SupplyChainMember jnj:MedicalDevicesMember 2018-12-31 2019-06-30 0000200406 jnj:OtherIncomeExpenseNetMember jnj:SupplyChainMember 2019-04-01 2019-06-30 0000200406 srt:MaximumMember jnj:SupplyChainMember jnj:MedicalDevicesMember 2018-12-31 2019-06-30 0000200406 jnj:OtherIncomeExpenseNetMember jnj:SupplyChainMember 2018-12-31 2019-06-30 0000200406 us-gaap:CostOfSalesMember jnj:SupplyChainMember 2019-04-01 2019-06-30 0000200406 jnj:SupplyChainMember 2018-12-31 2019-06-30 0000200406 us-gaap:OtherRestructuringMember jnj:MedicalDevicesMember 2018-12-31 2019-06-30 0000200406 us-gaap:EmployeeSeveranceMember jnj:MedicalDevicesMember 2018-12-31 2019-06-30 0000200406 jnj:AssetWriteoffMember jnj:MedicalDevicesMember 2018-12-31 2019-06-30 0000200406 us-gaap:OtherRestructuringMember jnj:MedicalDevicesMember 2018-12-30 0000200406 jnj:MedicalDevicesMember 2018-12-31 2019-06-30 0000200406 jnj:AssetWriteoffMember jnj:MedicalDevicesMember 2019-06-30 0000200406 jnj:AssetWriteoffMember jnj:MedicalDevicesMember 2018-12-30 0000200406 jnj:MedicalDevicesMember 2019-06-30 0000200406 us-gaap:EmployeeSeveranceMember jnj:MedicalDevicesMember 2018-12-30 0000200406 jnj:MedicalDevicesMember 2018-12-30 0000200406 us-gaap:EmployeeSeveranceMember jnj:MedicalDevicesMember 2019-06-30 0000200406 us-gaap:OtherRestructuringMember jnj:MedicalDevicesMember 2019-06-30 xbrli:pure xbrli:shares iso4217:USD xbrli:shares iso4217:USD iso4217:JPY xbrli:shares iso4217:JPY jnj:patient jnj:claimant

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
 
 
 
 
Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

for the quarterly period ended June 30, 2019

or
 
 
 
 
Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
for the transition period from            to
Commission file number 1-3215
Johnson & Johnson
(Exact name of registrant as specified in its charter)
New Jersey
 
22-1024240
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification No.)

One Johnson & Johnson Plaza
New Brunswick , New Jersey 08933
(Address of principal executive offices)
Registrant’s telephone number, including area code ( 732 524-0400
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
 
Large accelerated filer
Accelerated filer
 
Non-accelerated filer
Smaller reporting company
 
Emerging growth company
 
 

If an emerging growth company, indicated by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No






SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT
Title of each class
Trading Symbol
Name of each exchange on which registered
Common Stock, Par Value $1.00
JNJ
New York Stock Exchange
4.75% Notes Due November 2019
JNJ
New York Stock Exchange
0.250% Notes Due January 2022
JNJ
New York Stock Exchange
0.650% Notes Due May 2024
JNJ
New York Stock Exchange
5.50% Notes Due November 2024
JNJ
New York Stock Exchange
1.150% Notes Due November 2028
JNJ
New York Stock Exchange
1.650% Notes Due May 2035
JNJ
New York Stock Exchange
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
On July 24, 2019, 2,639,165,527 shares of Common Stock, $1.00 par value, were outstanding.





JOHNSON & JOHNSON AND SUBSIDIARIES
TABLE OF CONTENTS
 
 
Page
 
 
No.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 





CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q and Johnson & Johnson's other publicly available documents contain forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Management and representatives of Johnson & Johnson and its subsidiaries (the Company) also may from time to time make forward-looking statements. Forward-looking statements do not relate strictly to historical or current facts and reflect management’s assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as “plans,” “expects,” “will,” “anticipates,” “estimates,” and other words of similar meaning in conjunction with, among other things: discussions of future operations, expected operating results, financial performance; impact of planned acquisitions and dispositions; impact and timing of restructuring initiatives including associated cost savings and other benefits; the Company's strategy for growth; product development activities; regulatory approvals; market position and expenditures.
Because forward-looking statements are based on current beliefs, expectations and assumptions regarding future events, they are subject to uncertainties, risks and changes that are difficult to predict and many of which are outside of the Company's control. Investors should realize that if underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, the Company’s actual results and financial condition could vary materially from expectations and projections expressed or implied in its forward-looking statements. Investors are therefore cautioned not to rely on these forward-looking statements. Risks and uncertainties include, but are not limited to:
Risks Related to Product Development, Market Success and Competition
Challenges and uncertainties inherent in innovation and development of new and improved products and technologies on which the Company’s continued growth and success depend, including uncertainty of clinical outcomes, additional analysis of existing clinical data, obtaining regulatory approvals, health plan coverage and customer access, and initial and continued commercial success;
Challenges to the Company’s ability to obtain and protect adequate patent and other intellectual property rights for new and existing products and technologies in the United States and other important markets;
The impact of patent expirations, typically followed by the introduction of competing biosimilars and generics and resulting revenue and market share losses;
Increasingly aggressive and frequent challenges to the Company’s patents by competitors and others seeking to launch competing generic, biosimilar or other products and increased receptivity of courts, the United States Patent and Trademark Office and other decision makers to such challenges, potentially resulting in loss of market exclusivity and rapid decline in sales for the relevant product sooner than expected;
Competition in research and development of new and improved products, processes and technologies, which can result in product and process obsolescence;
Competition to reach agreement with third parties for collaboration, licensing, development and marketing agreements for products and technologies;
Competition based on cost-effectiveness, product performance, technological advances and patents attained by competitors; and
Allegations that the Company’s products infringe the patents and other intellectual property rights of third parties, which could adversely affect the Company’s ability to sell the products in question and require the payment of money damages and future royalties.
Risks Related to Product Liability, Litigation and Regulatory Activity
Product efficacy or safety concerns, whether or not based on scientific evidence, potentially resulting in product withdrawals, recalls, regulatory action on the part of the United States Food and Drug Administration (or international counterparts), declining sales, reputational damage, increased litigation expense and share price impact;
Impact, including declining sales and reputational damage, of significant litigation or government action adverse to the Company, including product liability claims and allegations related to pharmaceutical marketing practices and contracting strategies;
Impact of an adverse judgment or settlement and the adequacy of reserves related to legal proceedings, including patent litigation, product liability, personal injury claims, securities class actions, government investigations, employment and other legal proceedings;



Increased scrutiny of the health care industry by government agencies and state attorneys general resulting in investigations and prosecutions, which carry the risk of significant civil and criminal penalties, including, but not limited to, debarment from government business;
Failure to meet compliance obligations in the McNEIL-PPC, Inc. Consent Decree or any other compliance agreements with governments or government agencies, which could result in significant sanctions;
Potential changes to applicable laws and regulations affecting United States and international operations, including relating to: approval of new products; licensing and patent rights; sales and promotion of health care products; access to, and reimbursement and pricing for, health care products and services; environmental protection and sourcing of raw materials;
Compliance with local regulations and laws that may restrict the Company’s ability to manufacture or sell its products in relevant markets including, requirements to comply with medical device reporting regulations and other requirements such as the European Union's Medical Devices Regulation;
Changes in domestic and international tax laws and regulations, including changes related to The Tax Cuts and Jobs Act in the United States, the Federal Act on Tax Reform and AHV Financing in Switzerland, increasing audit scrutiny by tax authorities around the world and exposures to additional tax liabilities potentially in excess of existing reserves; and
Issuance of new or revised accounting standards by the Financial Accounting Standards Board and regulations by the Securities and Exchange Commission.
Risks Related to the Company’s Strategic Initiatives and Health Care Market Trends
Pricing pressures resulting from trends toward health care cost containment, including the continued consolidation among health care providers and other market participants, trends toward managed care, the shift toward governments increasingly becoming the primary payers of health care expenses, significant new entrants to the health care markets seeking to reduce costs and government pressure on companies to voluntarily reduce costs and price increases;
Restricted spending patterns of individual, institutional and governmental purchasers of health care products and services due to economic hardship and budgetary constraints;
Challenges to the Company’s ability to realize its strategy for growth including through externally sourced innovations, such as development collaborations, strategic acquisitions, licensing and marketing agreements, and the potential heightened costs of any such external arrangements due to competitive pressures;
The potential that the expected strategic benefits and opportunities from any planned or completed acquisition or divestiture by the Company may not be realized or may take longer to realize than expected; and
The potential that the expected benefits and opportunities related to past and ongoing restructuring actions may not be realized or may take longer to realize than expected.
Risks Related to Economic Conditions, Financial Markets and Operating Internationally
Market conditions and the possibility that the Company’s share repurchase program may be delayed, suspended or discontinued;
Impact of inflation and fluctuations in interest rates and currency exchange rates and the potential effect of such fluctuations on revenues, expenses and resulting margins;
Potential changes in export/import and trade laws, regulations and policies of the United States and other countries, including any increased trade restrictions or tariffs and potential drug reimportation legislation;
The impact on international operations from financial instability in international economies, sovereign risk, possible imposition of governmental controls and restrictive economic policies, and unstable international governments and legal systems;
Changes to global climate, extreme weather and natural disasters that could affect demand for the Company's products and services, cause disruptions in manufacturing and distribution networks, alter the availability of goods and services within the supply chain, and affect the overall design and integrity of the Company's products and operations; and
The impact of armed conflicts and terrorist attacks in the United States and other parts of the world including social and economic disruptions and instability of financial and other markets.




Risks Related to Supply Chain and Operations
Difficulties and delays in manufacturing, internally through third party providers or otherwise within the supply chain, that may lead to voluntary or involuntary business interruptions or shutdowns, product shortages, withdrawals or suspensions of products from the market, and potential regulatory action;
Interruptions and breaches of the Company's information technology systems or those of the Company's vendors which, could result in reputational, competitive, operational or other business harm as well as financial costs and regulatory action;
Reliance on global supply chains and production and distribution processes that are complex and subject to increasing regulatory requirements that may adversely affect supply, sourcing and pricing of materials used in the Company’s products; and
The potential that the expected benefits and opportunities related to restructuring actions contemplated for the global supply chain may not be realized or may take longer to realize than expected, including due to any required approvals from applicable regulatory authorities. Disruptions associated with the announced global supply chain actions may adversely affect supply and sourcing of materials used in the Company's products.
Investors also should carefully read the Risk Factors described in Item 1A of the Company's Annual Report on Form 10-K for the fiscal year ended December 30, 2018, for a description of certain risks that could, among other things, cause the Company’s actual results to differ materially from those expressed in its forward-looking statements. Investors should understand that it is not possible to predict or identify all such factors and should not consider the risks described above to be a complete statement of all potential risks and uncertainties. The Company does not undertake to publicly update any forward-looking statement that may be made from time to time, whether as a result of new information or future events or developments.




Part I — FINANCIAL INFORMATION

Item 1 — FINANCIAL STATEMENTS

JOHNSON & JOHNSON AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(Unaudited; Dollars in Millions Except Share and Per Share Data)
 
 
June 30, 2019
 
December 30, 2018
ASSETS
Current assets:
 
 
 
 
Cash and cash equivalents
 
$
14,376

 
18,107

Marketable securities
 
902

 
1,580

Accounts receivable, trade, less allowances for doubtful accounts $251 (2018, $248)
 
14,653

 
14,098

Inventories (Note 2)
 
9,263

 
8,599

Prepaid expenses and other
 
2,411

 
2,699

Assets held for sale (Note 10)
 
194

 
950

Total current assets
 
41,799

 
46,033

Property, plant and equipment at cost
 
42,905

 
41,851

Less: accumulated depreciation
 
(25,657
)
 
(24,816
)
Property, plant and equipment, net
 
17,248

 
17,035

Intangible assets, net (Note 3)
 
49,332

 
47,611

Goodwill (Note 3)
 
33,661

 
30,453

Deferred taxes on income
 
7,647

 
7,640

Other assets
 
5,430

 
4,182

Total assets
 
$
155,117

 
152,954

LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
 
 
 
 
Loans and notes payable
 
$
1,719

 
2,796

Accounts payable
 
6,912

 
7,537

Accrued liabilities
 
8,297

 
7,601

Accrued rebates, returns and promotions
 
10,433

 
9,380

Accrued compensation and employee related obligations
 
2,291

 
3,098

Accrued taxes on income
 
1,701

 
818

Total current liabilities
 
31,353

 
31,230

Long-term debt (Note 4)
 
27,699

 
27,684

Deferred taxes on income
 
7,725

 
7,506

Employee related obligations
 
9,910

 
9,951

Long-term taxes payable
 
7,543

 
8,242

Other liabilities
 
10,102

 
8,589

Total liabilities
 
94,332

 
93,202

Commitments and Contingencies (Note 11)
 


 


Shareholders’ equity:
 
 
 
 
Common stock — par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)
 
$
3,120

 
3,120

Accumulated other comprehensive income (loss) (Note 7)
 
(14,969
)
 
(15,222
)
Retained earnings
 
109,809

 
106,216

Less: common stock held in treasury, at cost (477,778,000 and 457,519,000 shares)
 
37,175

 
34,362

Total shareholders’ equity
 
60,785

 
59,752

Total liabilities and shareholders' equity
 
$
155,117

 
152,954

See Notes to Consolidated Financial Statements

1


JOHNSON & JOHNSON AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF EARNINGS
(Unaudited; Dollars & Shares in Millions Except Per Share Amounts)
 
 
Fiscal Second Quarter Ended
 
 
June 30,
2019
 
Percent
to Sales
 
July 1,
2018
 
Percent
to Sales
Sales to customers (Note 9)
 
$
20,562

 
100.0
 %
 
$
20,830

 
100.0
 %
Cost of products sold
 
6,940

 
33.8

 
6,927

 
33.3

Gross profit
 
13,622

 
66.2

 
13,903

 
66.7

Selling, marketing and administrative expenses
 
5,546

 
27.0

 
5,743

 
27.5

Research and development expense
 
2,666

 
13.0

 
2,639

 
12.7

Interest income
 
(88
)
 
(0.4
)
 
(126
)
 
(0.6
)
Interest expense, net of portion capitalized
 
83

 
0.4

 
253

 
1.2

Other (income) expense, net
 
(1,683
)
 
(8.2
)
 
364

 
1.7

Restructuring (Note 12)
 
57

 
0.2

 
57

 
0.3

Earnings before provision for taxes on income
 
7,041

 
34.2

 
4,973

 
23.9

Provision for taxes on income (Note 5)
 
1,434

 
6.9

 
1,019

 
4.9

NET EARNINGS
 
$
5,607

 
27.3
 %
 
$
3,954

 
19.0
 %
 
 
 
 
 
 
 
 
 
NET EARNINGS PER SHARE (Note 8)
 
 
 
 
 
 
 
 
Basic
 
$
2.11

 
 
 
$
1.47

 
 
Diluted
 
$
2.08

 
 
 
$
1.45

 
 
 
 
 
 
 
 
 
 
 
AVG. SHARES OUTSTANDING
 
 
 
 
 
 
 
 
Basic
 
2,652.5

 
 
 
2,682.3

 
 
Diluted
 
2,691.7

 
 
 
2,721.3

 
 


See Notes to Consolidated Financial Statements



2


JOHNSON & JOHNSON AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF EARNINGS
(Unaudited; Dollars & Shares in Millions Except Per Share Amounts)
 
 
 
 
 
 
 
 
 
 
 
Fiscal Six Months Ended
 
 
June 30,
2019
 
Percent
to Sales
 
July 1,
2018
 
Percent
to Sales
Sales to customers (Note 9)
 
$
40,583

 
100.0
 %
 
$
40,839

 
100.0
 %
Cost of products sold
 
13,555

 
33.4

 
13,541

 
33.2

Gross profit
 
27,028

 
66.6

 
27,298

 
66.8

Selling, marketing and administrative expenses
 
10,765

 
26.5

 
11,006

 
27.0

Research and development expense
 
5,524

 
13.6

 
5,043

 
12.3

In-process research and development
 
890

 
2.2

 

 

Interest income
 
(187
)
 
(0.5
)
 
(240
)
 
(0.6
)
Interest expense, net of portion capitalized
 
185

 
0.5

 
512

 
1.3

Other (income) expense, net
 
(1,705
)
 
(4.2
)
 
424

 
1.0

Restructuring (Note 12)
 
93

 
0.3

 
99

 
0.2

Earnings before provision for taxes on income
 
11,463

 
28.2

 
10,454

 
25.6

Provision for taxes on income (Note 5)
 
2,107

 
5.1

 
2,133

 
5.2

NET EARNINGS
 
$
9,356

 
23.1
 %
 
$
8,321

 
20.4
 %
 
 
 
 
 
 
 
 
 
NET EARNINGS PER SHARE (Note 8)
 
 
 
 
 
 
 
 
Basic
 
$
3.52

 
 
 
$
3.10

 
 
Diluted
 
$
3.47

 
 
 
$
3.05

 
 
 
 
 
 
 
 
 
 
 
AVG. SHARES OUTSTANDING
 
 
 
 
 
 
 
 
Basic
 
2,656.7

 
 
 
2,682.2

 
 
Diluted
 
2,697.0

 
 
 
2,728.5

 
 
 
 
 
 
 
 
 
 
 
See Notes to Consolidated Financial Statements



3


JOHNSON & JOHNSON AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(Unaudited; Dollars in Millions)

 
Fiscal Second Quarter Ended
 
Fiscal Six Months Ended
 
June 30, 2019
 
July 1, 2018
 
June 30, 2019
 
July 1, 2018
Net earnings
$
5,607

 
3,954

 
$
9,356

 
8,321

 
 
 
 
 
 
 
 
Other comprehensive income (loss), net of tax
 
 
 
 
 
 
 
Foreign currency translation
350

 
(2,190
)
 
92

 
(1,567
)
 
 
 
 
 
 
 
 
Securities:
 
 
 
 
 
 
 
  Unrealized holding gain (loss) arising during period
1

 

 
1

 

  Reclassifications to earnings

 

 

 

  Net change
1

 

 
1

 

 
 
 
 
 
 
 
 
Employee benefit plans:
 
 
 
 
 
 
 
  Prior service cost amortization during period
(5
)
 
(5
)
 
(12
)
 
(11
)
  Gain (loss) amortization during period
142

 
190

 
318

 
382

  Net change
137

 
185

 
306

 
371

 
 
 
 
 
 
 
 
Derivatives & hedges:
 
 
 
 
 
 
 
  Unrealized gain (loss) arising during period
86

 
(61
)
 
(216
)
 
(225
)
  Reclassifications to earnings
(26
)
 
(103
)
 
70

 
75

  Net change
60

 
(164
)
 
(146
)
 
(150
)
 
 
 
 
 
 
 
 
Other comprehensive income (loss)
548

 
(2,169
)
 
253

 
(1,346
)
 
 
 
 
 
 
 
 
Comprehensive income
$
6,155

 
1,785

 
$
9,609

 
6,975

 
 
 
 
 
 
 
 
See Notes to Consolidated Financial Statements

The tax effects in other comprehensive income for the fiscal second quarter were as follows for 2019 and 2018, respectively: Foreign Currency Translation: $106 million and $346 million; Employee Benefit Plans: $34 million and $51 million; Derivatives & Hedges: $16 million and $44 million.
 
The tax effects in other comprehensive income for the fiscal six months were as follows for 2019 and 2018, respectively: Foreign Currency Translation: $44 million and $183 million; Employee Benefit Plans: $35 million and $103 million; Derivatives & Hedges:$39 million and $40 million.
 

4


JOHNSON & JOHNSON AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF EQUITY
(Unaudited; Dollars in Millions)



Fiscal Second Quarter Ended June 30, 2019

 
Total
 
Retained
Earnings
 
Accumulated
Other
Comprehensive
Income
 
Common Stock
Issued Amount
 
Treasury
Stock
Amount
Balance, March 31, 2019
$
58,955

 
106,650

 
(15,517
)
 
3,120

 
(35,298
)
Net earnings
5,607

 
5,607

 

 

 

Cash dividends paid ($0.95 per share)
(2,522
)
 
(2,522
)
 

 

 

Employee compensation and stock option plans
683

 
74

 

 

 
609

Repurchase of common stock
(2,486
)
 

 

 

 
(2,486
)
Other

 

 

 

 

Other comprehensive income (loss), net of tax
548

 

 
548

 

 

Balance, June 30, 2019
$
60,785

 
109,809

 
(14,969
)
 
3,120

 
(37,175
)



Fiscal Six Months Ended June 30, 2019

 
Total
 
Retained
Earnings
 
Accumulated
Other
Comprehensive
Income
 
Common Stock
Issued Amount
 
Treasury
Stock
Amount
Balance, December 30, 2018
$
59,752

 
106,216

 
(15,222
)
 
3,120

 
(34,362
)
Net earnings
9,356

 
9,356

 

 

 

Cash dividends paid ($1.85 per share)
(4,918
)
 
(4,918
)
 

 

 

Employee compensation and stock option plans
1,034

 
(845
)
 

 

 
1,879

Repurchase of common stock
(4,692
)
 

 

 

 
(4,692
)
Other

 

 

 

 

Other comprehensive income (loss), net of tax
253

 

 
253

 

 

Balance, June 30, 2019
$
60,785

 
109,809

 
(14,969
)
 
3,120

 
(37,175
)


See Notes to Consolidated Financial Statements














5


JOHNSON & JOHNSON AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF EQUITY (cont.)
(Unaudited; Dollars in Millions)



Fiscal Second Quarter Ended July 1, 2018

 
Total
 
Retained
Earnings
 
Accumulated
Other
Comprehensive
Income
 
Common Stock
Issued Amount
 
Treasury
Stock
Amount
Balance, April 1, 2018
$
63,255

 
104,339

 
(12,608
)
 
3,120

 
(31,596
)
Cumulative Adjustment to retained earnings

 

 

 

 

Net earnings
3,954

 
3,954

 

 

 

Cash dividends paid ($0.90 per share)
(2,415
)
 
(2,415
)
 

 

 

Employee compensation and stock option plans
409

 
245

 

 

 
164

Repurchase of common stock
(145
)
 

 

 

 
(145
)
Other

 

 

 

 

Other comprehensive income (loss), net of tax
(2,169
)
 

 
(2,169
)
 

 

Balance, July 1, 2018
$
62,889

 
106,123

 
(14,777
)
 
3,120

 
(31,577
)
 
 
 
 
 
 
 
 
 
 



Fiscal Six Months Ended July 1, 2018

 
Total
 
Retained
Earnings
 
Accumulated
Other
Comprehensive
Income
 
Common Stock
Issued Amount
 
Treasury
Stock
Amount
Balance, December 31, 2017
$
60,160

 
101,793

 
(13,199
)
 
3,120

 
(31,554
)
Cumulative Adjustment to retained earnings
1,264

 
1,496

 
(232
)
 

 

Net earnings
8,321

 
8,321

 

 

 

Cash dividends paid ($1.74 per share)
(4,668
)
 
(4,668
)
 

 

 

Employee compensation and stock option plans
760

 
(806
)
 

 

 
1,566

Repurchase of common stock
(1,589
)
 

 

 

 
(1,589
)
Other
(13
)
 
(13
)
 

 

 

Other comprehensive income (loss), net of tax
(1,346
)
 

 
(1,346
)
 

 

Balance, July 1, 2018
$
62,889

 
106,123

 
(14,777
)
 
3,120

 
(31,577
)
 
 
 
 
 
 
 
 
 
 


See Notes to Consolidated Financial Statements


6


JOHNSON & JOHNSON AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited; Dollars in Millions)
 
 
Fiscal Six Months Ended
 
 
June 30,
2019
 
July 1,
2018
CASH FLOWS FROM OPERATING ACTIVITIES
 
 
 
 
Net earnings
 
$
9,356

 
8,321

Adjustments to reconcile net earnings to cash flows from operating activities:
 
 
 
 
Depreciation and amortization of property and intangibles
 
3,466

 
3,463

Stock based compensation
 
572

 
580

Asset write-downs
 
989

 
27

Net gain on sale of assets/businesses
 
(2,079
)
 
(443
)
Deferred tax provision
 
(694
)
 
(285
)
Accounts receivable allowances
 
1

 
(16
)
Changes in assets and liabilities, net of effects from acquisitions and divestitures:
 
 
 
 
Increase in accounts receivable
 
(336
)
 
(989
)
Increase in inventories
 
(423
)
 
(491
)
Decrease in accounts payable and accrued liabilities
 
(444
)
 
(49
)
Increase in other current and non-current assets
 
(862
)
 
(267
)
Decrease in other current and non-current liabilities
 
(55
)
 
(166
)
 
 
 
 
 
NET CASH FLOWS FROM OPERATING ACTIVITIES
 
9,491

 
9,685

 
 
 
 
 
CASH FLOWS FROM INVESTING ACTIVITIES
 
 
 
 
Additions to property, plant and equipment
 
(1,493
)
 
(1,533
)
Proceeds from the disposal of assets/businesses, net
 
3,018

 
870

Acquisitions, net of cash acquired
 
(5,346
)
 
(222
)
Purchases of investments
 
(1,517
)
 
(951
)
Sales of investments
 
2,132

 
743

Other
 
1

 
(33
)
 
 
 
 
 
NET CASH USED BY INVESTING ACTIVITIES
 
(3,205
)
 
(1,126
)
 
 
 
 
 
CASH FLOWS FROM FINANCING ACTIVITIES
 
 
 
 
Dividends to shareholders
 
(4,918
)
 
(4,668
)
Repurchase of common stock
 
(4,692
)
 
(1,589
)
Proceeds from short-term debt
 
15

 
27

Retirement of short-term debt
 
(12
)
 
(2,433
)
Proceeds from long-term debt, net of issuance costs
 
1

 
3

Retirement of long-term debt
 
(1,005
)
 
(9
)
Proceeds from the exercise of stock options/employee withholding tax on stock awards, net
 
463

 
162

Other
 
98

 
(137
)
 
 
 
 
 
NET CASH USED BY FINANCING ACTIVITIES
 
(10,050
)
 
(8,644
)
 
 
 
 
 
Effect of exchange rate changes on cash and cash equivalents
 
33

 
(170
)
Decrease in cash and cash equivalents
 
(3,731
)
 
(255
)
Cash and Cash equivalents, beginning of period
 
18,107

 
17,824

CASH AND CASH EQUIVALENTS, END OF PERIOD
 
$
14,376

 
17,569

 
 
 
 
 
Acquisitions
 
 
 
 
Fair value of assets acquired
 
$
6,744

 
334

Fair value of liabilities assumed and noncontrolling interests
 
(1,398
)
 
(112
)
Net cash paid for acquisitions
 
$
5,346

 
222


See Notes to Consolidated Financial Statements

7


NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 — The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of Johnson & Johnson and its subsidiaries (the Company) and related notes as contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 30, 2018 . The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented.

Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.

New Accounting Standards
Recently Adopted Accounting Standards
ASU 2016-02 : Leases
The Company adopted this standard as of the beginning of fiscal year 2019, on a prospective basis. This update requires the recognition of lease assets and lease liabilities on the balance sheet for all lease obligations and disclosing key information about leasing arrangements. This update requires the recognition of lease assets and lease liabilities by lessees for arrangements that are classified as operating leases. The Company’s operating leases resulted in the recognition of additional assets and the corresponding liabilities on its Consolidated Balance Sheet, however it did not have a material impact on the consolidated financial statements.

The Company determines whether an arrangement is a lease at contract inception by establishing if the contract conveys the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration.
Right of Use (ROU) Assets and Lease Liabilities for operating leases are included in Other assets, Accrued liabilities, and Other liabilities on the consolidated balance sheet. The ROU Assets represent the right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. Commitments under finance leases are not significant, and are included in Property, plant and equipment, Loans and notes payable, and Long-term debt on the consolidated balance sheet.
ROU Assets and Lease Liabilities are recognized at the lease commencement date based on the present value of all minimum lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments, when the implicit rate is not readily determinable. Lease terms may include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term.
The Company has elected the following policy elections on adoption: use of portfolio approach on leases of assets under master service agreements, exclusion of short term leases on the balance sheet, and not separating lease and non-lease components.
The Company primarily has operating leases for space, vehicles, manufacturing equipment, and data processing equipment. Leases have remaining lease terms ranging from 1 year to 37 years , some of which could include options to extend the leases when they are reasonably certain.
As noted in the Company’s 2018 10-K, the approximate minimum rental payments required under operating leases that had initial or remaining non-cancelable lease terms in excess of one year at December 30, 2018 were:
(Dollars in Millions)
2019
 
2020
 
2021
 
2022
 
2023
 
After 2023
 
Total
$223
 
188
 
154
 
116
 
76
 
139
 
896


Commitments under finance leases are not significant.




8



Maturity of Lease Liabilities related to Operating Lease
The minimum rental payments required under operating leases that have initial or remaining non-cancellable lease terms in excess of one year as of June 30, 2019 are:
 (Dollars in Millions)
Operating Leases
2019 (for the remainder of fiscal 2019)
$
185

2020
245

2021
201

2022
156

2023
98

After 2023
214

Total lease payments
1,099

Less: Interest
88

Present Value of lease liabilities
$
1,011



The Weighted Average Remaining Lease Term and discount rate:
Operating leases                         6.2 years
Weighted Average Discount Rate                 3%
For the fiscal second quarter and first fiscal six months ended June 30, 2019, the operating lease costs were $50 million and $124 million , respectively. Cash paid for amounts included in the measurement of lease liabilities were $76 million and $147 million for the fiscal second quarter and fiscal six months of 2019, respectively. Other supplemental information related to these leases are as follows:
Supplemental balance sheet information (for the fiscal first quarter ended June 30, 2019) :
(Dollars in Millions)
 
 
Non-current operating lease right-of-use assets
 
$
980

Current operating lease liabilities
 
262

Non-current Operating lease liabilities
 
749

       Total operating lease liabilities
 
$
1,011

 
 
 
        
ASU 2018-02 : Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income
This update allows a Company to elect to reclassify stranded tax effects resulting from the Tax Cuts and Job Act enacted in December 2017 from accumulated other comprehensive income to retained earnings. The Company has elected not to reclassify the income tax effects of this standard and therefore this standard will not impact the Company's consolidated financial statements.

ASU 2018-16 : Derivatives and Hedging (Topic ASC 815)
This update adds the Overnight Index Swap (OIS) rate based on the Secured Overnight Financing Rate (SOFR) as an eligible benchmark interest rate permitted in the application of hedge accounting. The guidance was effective for the Company as of the fiscal fourth quarter of 2018, due to the previous adoption of ASU 2017-12. The impact of the adoption of this guidance did not have a material impact on the Company’s consolidated financial statements and related disclosures. The standard may have an impact in the future as the market for SOFR derivatives develops over time and if SOFR is used to hedge the Company’s financial instruments.

Recently Issued Accounting Standards
Not Adopted as of June 30, 2019
ASU 2018-18 : Collaborative Arrangements

9


This update clarifies the interaction between ASC 808, Collaborative Arrangements and ASC 606, Revenue from Contracts with Customers. The update clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. In addition, the update precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue if the counterparty is not a customer for that transaction. This update will be effective for the Company for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. ASU 2018-18 should be applied retrospectively to the date of initial application of ASC 606 and early adoption is permitted. The Company is currently assessing the impact of this update on the Company’s consolidated financial statements and related disclosures.

ASU 2016-13 : Financial Instruments - Credit Losses
This update introduces the current expected credit loss (CECL) model, which will require an entity to measure credit losses for certain financial instruments and financial assets, including trade receivables. Under this update, on initial recognition and at each reporting period, an entity will be required to recognize an allowance that reflects the entity’s current estimate of credit losses expected to be incurred over the life of the financial instrument. This update will be effective for the Company for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years. Early adoption is permitted. The Company is currently assessing the impact of this update on the Company’s consolidated financial statements and related disclosures.


NOTE 2 — INVENTORIES
(Dollars in Millions)
 
June 30, 2019
 
December 30, 2018
Raw materials and supplies
 
$
1,198

 
1,114

Goods in process
 
2,024

 
2,109

Finished goods
 
6,041

 
5,376

Total inventories (1)
 
$
9,263

 
8,599


(1) The balance as of June 30, 2019, does not include the assets held for sale related to the strategic collaboration with Jabil Inc. of approximately $0.2 billion . The balance as of December 30, 2018, does not include the assets held for sale related to the divestiture of the Advanced Sterilization Products (ASP) business of approximately $0.2 billion and $0.3 billion related to the strategic collaboration with Jabil Inc.

NOTE 3 — INTANGIBLE ASSETS AND GOODWILL

Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2018 . Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted.
(Dollars in Millions)
 
June 30, 2019
 
December 30, 2018
Intangible assets with definite lives:
 
 
 
 
Patents and trademarks — gross
 
$
36,582

 
35,194

Less accumulated amortization
 
11,500

 
9,784

Patents and trademarks — net
 
25,082

 
25,410

Customer relationships and other intangibles — gross
 
21,862

 
21,334

Less accumulated amortization
 
8,874

 
8,323

Customer relationships and other intangibles — net
 
12,988

 
13,011

Intangible assets with indefinite lives:
 
 
 
 
Trademarks
 
6,939

 
6,937

Purchased in-process research and development (1)
 
4,323

 
2,253

Total intangible assets with indefinite lives
 
11,262

 
9,190

Total intangible assets — net
 
$
49,332

 
47,611



(1) In the fiscal first quarter of 2019, the Company recorded an IPR&D impairment charge of $0.9 billion for the remaining intangible asset value related to the development program of AL-8176, an investigational drug for the treatment of Respiratory Syncytial Virus (RSV) and human metapneumovirus (hMPV) acquired with the 2014 acquisition of Alios Biopharma Inc. The impairment charge was based on

10


additional information, including clinical data, which became available and led to the Company's decision to abandon the development of AL-8176. A partial impairment charge of $0.8 billion was previously recorded in the fiscal third quarter of 2018 related to the development program of AL-8176. In the fiscal second quarter of 2019, the Company completed the acquisition of Auris Health, Inc. and recorded an in-process research and development intangible asset of $2.9 billion .


Goodwill as of June 30, 2019 was allocated by segment of business as follows:
(Dollars in Millions)
 
Consumer
 
Pharm
 
Med Devices
 
Total
Goodwill, net at December 30, 2018
 
$
8,670

 
9,063

 
12,720

 
30,453

Goodwill, related to acquisitions
 
1,196

 

 
2,019

 
3,215

Currency translation/Other
 
(49
)
 
41

 
1

 
(7
)
Goodwill, net at June 30, 2019
 
$
9,817

 
9,104

 
14,740

 
33,661



The weighted average amortization period for patents and trademarks is 12 years. The weighted average amortization period for customer relationships and other intangible assets is 21 years. The amortization expense of amortizable intangible assets included in cost of products sold was $1.1 billion for each of the fiscal second quarters ended June 30, 2019 and July 1, 2018 . The amortization expense of amortizable intangible assets included in cost of products sold was $2.2 billion for each of the fiscal six months ended June 30, 2019 and July 1, 2018 . The estimated amortization expense for the five succeeding years approximates $4.4 billion , before tax, per year. Intangible asset write-downs are included in Other (income) expense, net.

See Note 10 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.

NOTE 4 — FAIR VALUE MEASUREMENTS

The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany product and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings.
Both types of derivatives are designated as cash flow hedges.

Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges, and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities.

The Company early adopted ASU 2017-12: Targeted Improvements to Accounting for Hedge Activities effective as of the beginning of fiscal second quarter of 2018.

The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of June 30, 2019 , the total amount of collateral paid under the credit support agreements (CSA) amounted to $384 million , net. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of June 30, 2019 , the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $49.7 billion , $15.3 billion and $0.5 billion , respectively. As of December 30, 2018 , the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $41.1 billion , $7.3 billion and $0.5 billion , respectively.

All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.


11


The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings and are then reclassified to earnings in the same account as the hedged transaction. Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. Gains and losses on net investment hedges are accounted for through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued.

The Company designated its Euro denominated notes issued in May 2016 with due dates ranging from 2022 to 2035 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates.

As of June 30, 2019 , the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $341 million after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months , excluding interest rate contracts, net investment hedges and equity collar contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.


12


The following table is a summary of the activity related to derivatives and hedges for the fiscal second quarters ended in 2019 and 2018 :

 
June 30, 2019
July 1, 2018
(Dollars in Millions)
Sales
Cost of Products Sold
R&D Expense
Interest (Income) Expense
Other (Income) Expense
Sales
Cost of Products Sold
R&D Expense
Interest (Income) Expense
Other (Income) Expense
The effects of fair value, net investment and cash flow hedging:
 
 
 
 
 
 
 
 
 
 
Gain (Loss) on fair value hedging relationship:
 
 
 
 
 
 
 
 
 
 
Interest rate swaps contracts:
 
 
 
 
 
 
 
 
 
 
    Hedged items
$



1





5


    Derivatives designated as hedging instruments



(1
)




(5
)

 
 
 
 
 
 
 
 
 
 
 
Gain (Loss) on net investment hedging relationship:
 
 
 
 
 
 
 
 
 
 
Cross currency interest rate swaps contracts:
 
 
 
 
 
 
 
 
 
 
   Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing



39





2


   Amount of gain or (loss) recognized in AOCI



39





2


 
 
 
 
 
 
 
 
 
 
 
Gain (Loss) on cash flow hedging relationship:
 
 
 
 
 
 
 
 
 
 
Forward foreign exchange contracts:
 
 
 
 
 
 
 
 
 
 
   Amount of gain or (loss) reclassified from AOCI into income
(14
)
(101
)
36


2

17

76

(14
)

(10
)
 
 
 
 
 
 
 
 
 
 
 
   Amount of gain or (loss) recognized in AOCI

(50
)
18


(3
)
(49
)
(57
)
21


3

 
 
 
 
 
 
 
 
 
 
 
Cross currency interest rate swaps contracts:
 
 
 
 
 
 
 
 
 
 
   Amount of gain or (loss) reclassified from AOCI into income



64





32


   Amount of gain or (loss) recognized in AOCI
$



82





19


 
 
 
 
 
 
 
 
 
 
 



13


The following table is a summary of the activity related to derivatives and hedges for the fiscal six months ended in 2019 and 2018 :
 
June 30, 2019
July 1, 2018
(Dollars in Millions)
Sales
Cost of Products Sold
R&D Expense
Interest (Income) Expense
Other (Income) Expense
Sales
Cost of Products Sold
R&D Expense
Interest (Income) Expense
Other (Income) Expense
The effects of fair value, net investment and cash flow hedging:
 
 
 
 
 
 
 
 
 
 
Gain (Loss) on fair value hedging relationship:
 
 
 
 
 
 
 
 
 
 
Interest rate swaps contracts:
 
 
 
 
 
 
 
 
 
 
 Hedged items
$



1





10


 Derivatives designated as hedging instruments



(1
)




(10
)

 
 
 
 
 
 
 
 
 
 
 
Gain (Loss) on net investment hedging relationship:
 
 
 
 
 
 
 
 
 
 
Cross currency interest rate swaps contracts:
 
 
 
 
 
 
 
 
 
 
   Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing



78





2


   Amount of gain or (loss) recognized in AOCI



78





2


 
 
 
 
 
 
 
 
 
 
 
Gain (Loss) on cash flow hedging relationship:
 
 
 
 
 
 
 
 
 
 
Forward foreign exchange contracts:
 
 
 
 
 
 
 
 
 
 
   Amount of gain or (loss) reclassified from AOCI into income
(35
)
(136
)
(103
)

8

46

78

(252
)

(21
)
 
 
 
 
 
 
 
 
 
 
 
   Amount of gain or (loss) recognized in AOCI
(6
)
(346
)
(92
)

10

(18
)
(54
)
(216
)

(15
)
 
 
 
 
 
 
 
 
 
 
 
Cross currency interest rate swaps contracts:
 
 
 
 
 
 
 
 
 
 
   Amount of gain or (loss) reclassified from AOCI into income



118





72


   Amount of gain or (loss) recognized in AOCI
$



140





76


 
 
 
 
 
 
 
 
 
 
 









14


As of June 30, 2019 , and December 30, 2018 , the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges:
Line item in the Consolidated Balance Sheet in which the hedged item is included
 
Carrying Amount of the Hedged Liability

 
Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability
(Dollars in Millions)
 
June 30, 2019
 
December 30, 2018
 
June 30, 2019
 
December 30, 2018
Current Portion of Long-term Debt
 
$
498

 
494

 
1

 
5

Long-term Debt
 

 

 

 



The following table is the effect of derivatives not designated as hedging instrument for the fiscal second quarter and fiscal six months ended in 2019 and 2018:
 
 
 
 
Gain/(Loss)
Recognized In
Income on Derivative
Gain/(Loss)
Recognized In
Income on Derivative
(Dollars in Millions)
 
Location of Gain /(Loss) Recognized in Income on Derivative
 
Fiscal Second Quarter Ended
Fiscal Six Months Ended
Derivatives Not Designated as Hedging Instruments
 
 
 
June 30, 2019
 
July 1, 2018
June 30, 2019